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Dendritic cells (DCs) are able to stimulate T cell and initiate immune 
responses via the antigen presentation pathway which is regulated by major 
histocompatibility complex class II (MHC class II) and its accessory molecules 
such as invariant chain CD74 and MHC class II like molecule H2-M. The 
expression of these molecules is mainly controlled by class II transactivator 
(CIITA). CIITA is a non-DNA binding co-activator, and serves as a platform for 
the recruitment of various trans-factors which are require for successful 
transcription of MHC class II and its accessory molecules. Here, we identified and 
described the function of a novel isoform of CIITA, DC-expressed caspase 
inhibitory isoform of CIITA (DC-CASPIC). DC-CASPIC is expressed in 
immature DCs and its protein expression is up-regulated upon DC maturation. In 
mature DCs, DC-CASPIC localises to mitochondria and interacts with caspases 
thereby inhibiting caspase activities. Since nitric oxide synthase-2 (NOS2) is a 
substrate for caspases, DC-CASPIC thus inhibits the caspase-dependent 
degradation of NOS2 and induces nitric oxide (NO) synthesis in maturing DCs. 
Furthermore, similar to lipolysaccharide-treated DCs, DCs over-expressing DC-
CASPIC enhance MHC class II, CD80 and CD86 cell surface expression and 
stimulate T cell proliferation. Taken together, our results strongly suggest that 
DC-CASPIC is one of the key molecules that regulate NO synthesis and antigen 
presentation during maturation of DCs. 
Next, we dissected the detailed mechanism of NOS/NO-enhanced antigen 
presentation during maturation of DCs. We reported that in immature DCs, the 
NO donor and the over-expression of either NOS2 or NOS3 alone could induce 
the cell surface expression of MHC class II, CD80 and CD86. Consistently, NO 
vii 
 
donor-treated immature DCs were capable of enhancing T cell proliferation in 
vitro in the absence of lipolysaccharide. Interestingly, NOS2 interacted with CD74, 
and the degradation of CD74 by caspases in immature DCs was inhibited upon 
treatment with the NO donor. Since the trafficking of MHC class II is CD74-
dependent, the increase in cell surface localisation of MHC class II in maturing 
DCs could be partly due to the increase in CD74 protein expression in the 
presence of NOS2 and NO. These studies may provide a novel platform to 
enhance the antigen presentation ability of DCs and to develop or design potent 
vaccines against infectious diseases and cancers. 
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CHAPTER 1 OVERVIEW 
Dendritic cells (DCs) consist of a heterogeneous population of cells that 
accomplish key functions in the immune system, including the establishment of a 
central tolerance in the thymus, the maintenance of self-tolerance in the periphery 
and the initiation and regulation of an adaptive immune response (Banchereau et 
al., 2000). These functions of DCs are conferred by their ability to internalise, 
process and present antigens to T cells. The presentation of peptides to the antigen 
receptor on CD4+ T helper lymphocytes is mediated by the major 
histocompatibility complex class II molecules (MHC class II), invariant chain 
CD74 and MHC class II like molecule H2-M as well as other regulatory 
molecules. In this pathway, MHC class II and CD74 are assembled in the 
endoplasmic reticulum (ER) and transported to the endosomal membrane system. 
In the endosomal membrane system, CD74 (bound to the peptide-binding groove 
of the MHC II molecule) is degraded into a short peptide called class II associated 
invariant chain peptide (CLIP). Under the influence of H2-M function, CLIP is 
released and replaced by the antigenic peptides in the endosomes. The MHC class 
II and antigenic peptides form complexes, and then are transported to the cell 
surface and presented to T cells.  
Because CD4+ T cells only recognise antigen-derived peptides bound to 
MHC class II molecules but not free antigenic peptides, MHC class II molecules 
play a crucial role in the antigen presentation pathway. Accordingly, the lack of 
MHC class II at the cell surface results in an autosomal and recessive severe 
combined immunodeficiency called the bare lymphocyte syndrome. Moreover, 
their inappropriate expression on in target tissues results in organ-specific 
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autoimmunity (Reith and Mach, 2001). Hence, the expression of MHC class II in 
all antigen-presenting cells must be tightly controlled. In DCs, MHC class II is 
regulated (1) at the transcriptional level by the MHC class II transcription 
activator (CIITA) (Ting and Trowsdale, 2002), and (2) at the translational/post-
translational level by its chaperone, CD74 (Cresswell, 1994).  
The transcriptional regulation of MHC class II mainly occurs at its 
conserved up-stream sequence that stretches through 75 nucleotides containing 
and contains several cis-elements such as X box, Y box and S box. In this region, 
regulatory factor X (RFX) binds to the X and S boxes, whereas nuclear factor Y 
(NFY) binds to the Y box which is composed of the CCAAT sequence. Activator 
protein 1 (AP1), X2 binding domain (X2BP) and cAMP response element binding 
protein (CREB) interact with the X2 box. However, the presence of these 
transcription factors alone is not sufficient to initiate the transcription of MHC 
class II. The transcription of MHC class II takes place only after CIITA is 
recruited to provide a platform for the binding of these factors. This CIITA-
containing complex, which is called MHC class II enhanceosome, is thus essential 
for the expression of MHC class II. It also takes part in the regulation of CD74 
and H2-M transcription (Reith and Mach, 2001)  (Figure 1).  
 
Figure 1: Schematic of MHC class II enhanceosome 
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Unlike RFX and NFY, the expression of CIITA is highly regulated by four 
different promoters in humans (pI, pII, pIII, pIV) depending on the cell types 
(Figure 2). The product of pII is absent in mice; pIV is mainly expressed in thymic 
epithelial cells (TEC) and non-hematopietic origin cells; pIII is a lymphoid 
promoter that is active in B cells and plasmacytoid DCs (pDCs); pI is specifically 
activated in DCs and its translation product is called CIITA type I, or DC-CIITA 
(Muhlethaler-Mottet et al., 1997). Nickerson et al (2001) reported that in contrast 
to the translated products from pIII and pIV, the CIITA protein synthesised from 
pI contained an extra caspase recruitment domain, namely the CARD domain 
(Figure 2). Interestingly, unlike other CARD-containing proteins, DC-CIITA does 
not interact with caspases. However, the CARD-like domain specific to DC-
CIITA has a higher transactivation activity when compared to other forms of 
CIITA, which do not contain CARD-like domain. The molecular mechanisms that 
underlie the function of the CARD-like domain remain largely unknown. It was 
hypothesised that DC-CIITA’s CARD-like domain might recognise the CARD on 
unidentified proteins, possibly transcription factors, or proteins that coordinate 
with the CIITA complex to enhance the transactivation of the MHC class II gene 
(Nickerson et al., 2001). The elucidation of the function of the CARD-like domain 
will be particularly important in the understanding of the function of DCs because 
it has been shown that DC-CIITA expression in DCs is driven mainly by pI, and 
that DC-CIITA transcripts are by far the most abundant compared with pIII and 
pIV products. mRNA transcripts in immature DCs (Leibundgut-Landmann et al., 
2004). 
As an initial step for this study, the CARD domain of DC-CIITA was 
cloned by RT-PCR with specific primers. Interestingly, in addition to the expected 
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DC-CIITA PCR product, an extra and larger PCR product was generated. Its 
sequence revealed a new open reading frame (ORF) that can be translated into a 
novel protein composed of a CARD domain of DC-CIITA and a 28-amino acid 
tail that has no significant homology to any known proteins/peptides in the Entrez 
database. This novel protein was named DC-CASPIC.  
 
Figure 2: Modular structure of regulatory region of gene encoding CIITA 
The subsequent functional study on DC-CASPIC revealed that increase of 
NO concentration resulted in DC-CASPIC over-expression in DCs-inhibited 
caspase activity, and elevated cell surface expression of MHC class II in DCs. In 
order to successfully transport to cell surface and present the antigenic peptide to 
response T cells, MHC class II needs the help from its chaperone, CD74. CD74 
stabilises the MHC class II molecules, prevents premature peptide loading and 
target MHC class II molecules to late endosomal compartments. In addition, 
CD74 also controls the proteolysis of H2-M protein which is required for efficient 
MHC class II antigenic peptide loading  (Pierre and Mellman, 1998; Pierre et al., 
2000).  
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Unlike CIITA, which is controlled by different promoters at transcriptional 
level, CD74 expression is highly regulated via stepwise proteolysis events. Full-
length CD74 (p31) bound to the MHC class II molecule is cleaved by proteases to 
give rise to p22, and then p10. P10 is further digested into the MHC class II-
associated invariant chain peptide CLIP. CLIP then dissociates from MHC class II 
with the help of H2-M, which facilitates the exchange of CLIP for the antigenic 
peptides (Figure 3) (Denzin and Cresswell, 1995; Hsing and Rudensky, 2005). 
Despite the identification of the various degradation products of CD74, the exact 
pathway of CD74 degradation remains unclear. Although the endoproteases 
responsible for the initiation of CD74 proteolysis have been reported to be a 
leupeptin-insensitive protease, its identity is still unclear. For example, asparagine 
endopeptidase (AEP) has been earlier reported to cleave CD74 in B cells 
(Manoury et al., 2003). However, it was later found to be dispensable in a study 
using AEP-knockout mice (Matza et al., 2003; Maehr et al., 2005). Pierre and 
Mellman proposed that cystatin C might predominantly control the regulation of 
CD74 protein degradation via the inhibition of activity of cathepsin S which was 
essentially involved in generating CLIP (Pierre and Mellman, 1998). Nevertheless, 
no co-localisation of cystatin C with the MHC class II compartments has been 
detected in either immature or mature DCs (Villadangos et al., 2001).  Moreover, 
knockout of the cystatin C gene has no effect on antigen presentation (El-Sukkari 
et al., 2003). These discrepancies suggest that other proteases might be involved 
in CD74 degradation. 
Previous work has shown that in immature DCs, a number of membrane 
trafficking-related proteins are degraded by caspases. In mature DCs, this caspase-
mediated degradation is inhibited presumably by a mechanism closely linked to 
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the activity of nitric oxide synthase 2 (NOS2), that catalyses the production of 
nitric oxide (NO) in large amounts during maturation of DCs (Wong et al., 2004; 
Santambrogio et al., 2005). Our results also indicate that NOS2 and caspase may 
be involved in the regulation of CD74 proteolysis in DCs. 
 
Figure 3: Schematic of CD74 degradation pathway 
Therefore, the scope of this study includes: (1) Isolation of full-length DC-
CASPIC cDNA; (2). Characterisation of DC-CASPIC expression profiles in 
mouse cell lines and tissues; (3) Analysis of DC-CASPIC function in DCs; (4) 
Identification of potential interaction partners of DC-CASPIC; (5) Identification 
of specific caspases that cleave CD74 in DCs; (6) Elucidation of NO-dependent 
mechanisms that regulate CD74 in DCs and (7) Analysis of the effects of CD74 
degradation on the function of DCs. 
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CHAPTER 2 LITERATURE REVIEW 
The mounting and regulation of effective adaptive immune responses 
heavily rely on antigen presentation. T cells are only able to recognise the 
pathogens/antigens that have been internalised by antigen-presenting cells (APCs) 
and processed into smaller fragments or peptides, which are then presented on the 
cell surface by MHC class I, II. MHC class I molecules are primarily essential for 
the presentation of cytosolic or viral antigens (Brigl and Brenner, 2004). MHC 
class I is also able to present exogenous peptides to T cells via the cross 
presentation pathway (Heath and Carbone, 2001). MHC class II molecules are 
predominantly expressed by antigen presenting cells (APCs) and they mostly 
present peptides derived from extracellular proteins to CD4+ T cells. MHC class II 
molecules present antigens to CD4+ T helper cells and thereby control the 
differentiation of B cells into antibody-producing B-cell blasts. Patients or mice 
failing to produce proper MHC class II–peptide complexes will not be able to 
raise sufficient antibody responses to infections. MHC class II is also important to 
modulate cytotoxic T-cell activation, autoimmune responses and other responses 
to pathogens or environmental antigens (Nuno Rocha et al, 2008). In the 
following literature review and study, the main focus will be on MHC class II 
mediated-antigen presentation pathway. 
In principle, any type of cells that express surface MHC are able to present 
antigens to T cells (Malissen et al., 1984). However, the efficiencies of antigen 
processing and presentation are vastly different (Mellman et al., 1998). Therefore, 
those types of cells displaying high capability of antigen processing and 
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presenting are dubbed as professional APCs. Typically, professional APCs include 
B cells, macrophages and DCs. B cells mainly present the antigen to CD4+ T cells. 
In turn, the CD4+ T cells stimulate the B cells to grow into plasma B cells that 
produce antibodies. In fact, the antigen presentation by B cells is intimately linked 
to their primary function in antibody secretion rather to T cell response. Unlike B 
cells, macrophages are able to stimulate T cells of various specificities. However, 
macrophages are not very efficient in antigen presentation because the internalised 
materials are easily digested instead of being processed into antigenic peptides in 
its lysosomal compartments (Mellman et al., 1998). In addition, compared with B 
cells and DCs, the amount of cell surface MHC class II is substantially lower on 
macrophage. This low level of MHC class II limits the macrophages’ efficiency in 
antigen presentation and T cell stimulation ex vivo and in vivo. The major function 
of macrophages may not be in the adaptive immune system but in the innate 
immune system, by clearance of invading pathogens. 
Unlike B cells and macrophages, antigen presentation appears to be the 
primary function of DCs. DCs are specialised for up taking, processing and 
presenting antigens to T cells via both MHC class I and class II pathway. And 
DCs are the only type of APCs which are capable of priming naïve T cells DCs 
(Randolph, 2001; Mempel et al., 2004). The next section provides more details on 
the DCs (Table 1) 
Table 1. Comparison of DCs, B cells and macrophages 
 Dendritic cells B cells Macrophages 
Antigen Internalization  +++  +  +++  
Surface MHC class II  +++  ++  +/-  
Primary Function  Antigen presentation Ab production Pathogen clearance  
Cross-presentation  +++  +/-  +/-  
Naïve T cell priming  +++  +/-  -  
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2.1 Dendritic cells 
2.1.1 Heterogeneity of DCs 
The heterogeneity of DCs is indicated by their different precursors, life 
cycle, cell surface markers, localisation and different phenotypes (Villadangos et 
al., 2007; Shortman and Naik, 2007). Based on their precursors, DCs in mice can 
be classified into three categories: (1) lymphoid-derived DCs (plasmacytoid DCs, 
pDCs), (2) myeloid-derived DCs (conventional DCs, cDCs) and (3) monocyte-
derived DCs which are also called TNF-iNOS-producing DCs or inflammatory 
DCs (Tip DCs) (Ardavin, 2003).  
pDCs are round, non-dendritic circulating DCs and exist in blood as well 
as in peripheral lymphoid organs. pDCs are distinguished from cDCs and TipDCs 
by expression of unique surface markers: CD123, CD303 and CD304, but not  
CD11c and CD14. In mouse, pDCs are also expressed B220 which is one of CD45 
isofrom (Hideki Nakano, 2001). Upon stimulation of double strand RNA (dsRNA) 
or CpG DNA, pDCs are able to produce type I interferon, for example IFN-α and 
IFN-β, which are critical pleiotropic anti-viral compounds (Asselin-Paturel, 2001). 
The second category of DCs, lymphoid-tissue-resident cDCs can be divided into 
CD8- and CD8+ subpopulations. Both subsets of cDCs can be induced undergo 
maturation. CD8- and CD8+ cDCs have different immune functions. CD8- cDCs 
mainly elicit T helper 2 (Th2)-cell response, whereas CD8+ induce strong Th1-cell 
response because of its high level of interlukin-12 (IL-12) production. Moreover, 
only CD8+ cDCs are able to internalise apoptotic cells (Shortman and Naik, 2007).   
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The third category of DCs is TipDCs. TipDCs are characterised by the 
production of tumor necrosis factor (TNF) and NOS2. In addition, TipDCs can be 
distinguished from cDCs by their intermediate rather than high expression level of 
CD11c and CD11b, and by the absence of CD4 or CD8 expression (Shortman and 
Naik, 2007). TipDCs are circulating DCs but they can be recruited to inflamed 
tissue in a chemokine (C-C motif) receptor 2 (CCR2)-dependent manner (Miguel, 
et al. 2004). TipDCs are important during both bacteria and virus infection. In L. 
monocytogenes infection, TipDCs mediate an effective immune response at the 
time when other subsets of DCs are not competent to mount responses against 
infection. They are also predominant source of TNF and NOS2 and mediate innate 
immune response (Leon, et al., 2007). In influenza infection, it is reported that 
TipDCs are required for the further proliferation of influenza-specific CD8+ T 
cells in the infected lung (Natalya, 2003). 
In vitro, Tip DCs can be derived from bone marrow cultures in the present 
of granulocyte monocyte colony stimulating factor (GM-CSF). These bone 
marrow derived DCs (BMDCs) display phenotypic and functional characteristics 
that are similar to TipDCs in vivo. The BMDCs are positive for CD11c, MHC 
class II and negative for T and B cell markers. And they also have a high T-cell 
stimulation capacity (Ardavin, 2003). More importantly, they express high level of 
NOS2 and TNF during maturation (Berthier, 2000). Shen et al. (1997) also 
developed a TipDC clones (DC2.4) by introducing the GM-CSF gene into the 
C57BL/6 bone marrow cells, followed by infection with a retrovirus encoding myc 
and raf oncogenes. Similar to Tip DCs in vivo and BMDCs in vitro, they express 
DCs specific markers including MHC class I, MHC class II, CD80, CD86 and 
CD205, and express NOS2 and TNF production DCs upon stimulation. Both of 
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BMDCs and DC2.4 cell are able to internalise, process and present antigens to T 
cells as peptides in the context of MHC class I and MHC class II molecules (Akira 
Takashima, 2001 and Suzanne, 2008). 
2.1.2 Maturation of DCs 
There are three developmental stages in DCs: dendritic cell precursors, 
immature DCs and mature DCs. The two latter stages are closely related to the 
different immune functions of DCs. The immature DCs exhibit a high capability 
in antigen capturing and processing but low efficiency in T cell stimulation 
capability. During maturation, DCs undergo a series of changes: rearrangement of 
the cytoskeleton, reduction in phagocytic activity, acquisition of cellular motility, 
and increase in cell surface MHC class II, up-regulation of costimulatory 
molecules and secretion of cytokines. These changes work together to help DCs 
transit from immature antigen-capturing cells to mature antigen-presenting DCs 
(Banchereau et al., 2000). 
The maturation of DCs is initiated either by innate immunity maturation 
signals or by adaptive immunity maturation signals. The innate immunity 
maturation signals are included various pathogen-related molecules such as LPS, 
CpG RNA and double stranded RNA (dsRNA). The recognitions of these 
pathogen-related molecules are mainly attributed to Toll like receptors (TLR). In 
mouse, DCs express nine kinds of TLRs (from TLR1 to TLR 9) and each TLR has 
its own specific ligand. For example, TLR4 specifically interacts LPS and 
activates the NF-κB signalling pathway via the MyD88 dependent pathway 
(Banchereau et al., 2000; da Silva Correia et al., 2001). Besides, the maturation of 
DCs is also induced by immunity maturation signals including cytokines (CD40, 
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TNF-α, IL-6, IFN-γ, for example) and antigen-antibody and Fc Receptors (Ag-Ab 
IC) (Banchereau et al., 2000). 
Among all of these signals, LPS is one of most superior stimuli to induce 
DC maturation in regard to the concentration of co-stimulatory molecules and in 
regard to the kinetics of maturation. The percentage of mature DCs is quickly 
increasing and exceeded 95% only after 48 hours of stimulation. And the matured 
DCs exhibit a high concentration of cell surface markers especially co-stimulatory 
and MHC molecules (Matjaž Jeras, 2005). In this current study, the maturation of 
DCs was induced by LPS. 
After the activation of transcriptional factors, the expression of many 
genes are up-regulated, including co-stimulatory molecules CD80 and CD86, as 
well as cytokines IL-12 and IFN-γ (Harris et al., 2008). These molecules then 
enhance DCs so as to stimulate the activation of T cells. Besides the up-regulation 
of co-stimulatory molecules and the secretion of cytokines, the most fundamental 
change during the maturation of DCs is the redistribution of MHC class II that is, 
MHC class II moves from the intracellular membrane system where it is loaded 
with antigenic peptide, to the cell surface, whereby it presents the antigenic 
peptide to the T cells (Figure 4).  
 
Figure 4: Maturation of DCs 
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2.2 Antigen presentation in DCs 
DCs are able to induce either tolerance or immunity, depending on the 
subtype, location and developmental stage. Nevertheless, regardless of these 
factors, the immune activities of DCs hinge on antigen presentation and 
recognition by T cells in order to fulfil their immune activities. In other words, the 
functions of DCs are dependent on the antigen presentation pathway which is 
composed of three steps: antigen capture, antigen processing and antigen 
presenting. 
Immature DCs have a high capability to capture antigens through three 
different approaches: macropinocytosis, receptor-mediated endocytosis and 
phagocytosis (Wilson and Villadangos, 2005). DCs can also internalise peptide-
loaded heat shock proteins gp96 and Hsp70, which are ligands of TLR (Tsan and 
Gao, 2004). Differences in the mechanisms for capturing exogenous antigens offer 
opportunities for functional specialisations among different DCs subsets. For 
example, among cDCs, the DCs resident in thymus and spleen are most efficient 
at phagocytosing dead cells. Antigen receptors are also differentially expressed 
among DC subtypes. The differential expression of these receptors can provide 
each DC subset with distinct capacities to capture and initiate responses against 
specific pathogens. Nevertheless, no significant differences have been described in 
pinocytic activity among DC subsets (Villadangos and Schnorrer, 2007). 
After the antigens are engulfed into DCs, they are transported into the 
endo-membrane trafficking system (such as the phagosome, endosome and 
lysosome), and are “chopped” into antigenic peptides with the help of various 
proteases. The antigenic peptides are then loaded into MHC class II molecules in 
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lysosomes or in MHC class II compartments (MIIC). The classic pathway of 
antigen presentation can be briefly outlined as follows: The MHC class II αβ 
heterodimers initially assemble in the endoplasmic reticulum with CD74 which 
acts as a chaperone to stabilise the heterodimers, prevent premature peptide 
loading and target MHC class II molecules to late endosomal compartments. 
CD74 is then partially dissociated through a series of proteolytic cleavage events, 
leaving a residual peptide (class II-associated invariant chain peptide, CLIP) 
occupying the peptide-binding groove of the MHC class II molecule. The final 
release of CLIP and its replacement with antigenic peptides is catalysed by H2-M 
(HLA-DM in humans), which is independently targeted to late endosomal 
compartments. The resulting MHC class II-peptide complex is then transported to 
the cell surface where it awaits interactions with antigen-specific T cells. 
2.3 Regulation of antigen presentation in DCs 
Antigen presentation is up-regulated during the maturation of DCs since immature 
DCs display at the surface an empty, peptide-receptive form of MHC class II, but 
only a few MHCII-peptide complexes, whereas mature immunogenic DCs express 
only high levels of long-lived MHC class II-peptide complexes (Santambrogio et 
al., 1999;Villadangos et al., 2001). This change is partially due to the deactivation 
of Cdc42, which belongs to the family of small Rho GTPases in mature DCs 
(Jaksits et al., 2004). Cdc42 is hypothesised to transport MHC class II complexes 
from the cell membrane to lysosome-related MHCII compartments via the linker 
protein Wiskott-Aldrich syndrome protein (WASP) (Shurin et al., 2005). 
Although immature and mature DCs express similar amounts of Cdc42 protein, 
only immature DCs contain detectable active form of Cdc42 that binds to GTP. 
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The loss of Cdc42 activity inhibits actin polymerisation in mature DCs, and leads 
to an accumulation of MHC class II on the cell surface (Wendy S. Garrett, et al, 
2004). Antigen presentation by DCs is also efficiently regulated through the 
ubiquitination of MHC class II-β. In immature DCs, the MHC class II β chain is 
oligoubiquitinated after the degradation of associated CD74 in endosomes. The 
ubiquitination of the MHC class II β is inhibited in the LPS-induced mature DCs, 
resulting in the accumulation of MHC class II on the cell surface (van Niel et al., 
2006; Shin et al., 2006). Antigen presentation is controlled not only by the 
intracellular distribution of MHC class II, but also by the surface expression of 
MHC class II. 
2.3.1 Regulation of MHC class II expression by CIITA at the transcriptional 
level 
2.3.1.1 CIITA 
Earlier studies have established the critical role of the class II 
transactivator (CIITA) as a positive regulator or ‘master controller’ of MHC class 
II transcription (Ting and Trowsdale, 2002). A deficiency of CIITA or other 
factors, such as the RFX subunits, that are necessary for MHC class II 
transcription, results in the Bare Lymphocyte Syndrome (BLS) (Reith et al., 2001). 
Unlike classical transcription factors, CIITA does not directly bind DNA; however 
it interacts with RFX5, NFY and CREB, and it has been proposed to function as a 
scaffold to promote the assembly of these transcription factors (Zhu et al., 2000). 
MHC class II expression in thymic epithelial cells (TECs) and APCs strictly 
depends on the activation of the CIITA gene (Chang et al., 1996) and the silencing 
of the CIITA gene abrogates MHC class II expression (Silacci et al., 1994; van 
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den Elsen et al., 2000). In addition, the expression of antigen presentation-related 
genes such as CD74 and H2-M are also under the control of CIITA (Chin et al., 
1997; Masternak and Reith, 2002). In DCs, CIITA is involved in negative 
regulation of IL-10 expression as well (Yee et al., 2005).  
Both mouse and human CIITA genes are encoded on chromosome 16. An 
analysis of mouse genomic DNA reveals that CIITA is encoded by 19 exons 
(Accolla et al., 1986; Steimle et al., 1994). Four different isoforms of human 
CIITA transcripts have been identified (Muhlethaler-Mottet et al, 1997). These 
isoforms are expressed under the control of different promoters (Figure 1). Three 
of these promoters (pI, pIII and pIV) are strongly conserved in the mouse C2ta 
gene but a mouse equivalent of pII is not known and therefore is not discussed 
here. Through the differential usage of pI, pIII and pIV, the CIITA gene 
determines the cell-type-specific cytokine-induced, and developmentally 
modulated MHC class II expression. The specificity of these promoters has 
recently been defined in vivo by generating mice carrying targeted deletions of the 
regulatory region of the CIIta gene. These results show that pIV is essential for 
CIITA expression in TECs and cells of non-hematopoietic origin after IFN-γ 
stimulation and the lack of pIV results in the absence of MHC class II expression 
in TECs, which leads to the abrogation of positive CD4+ T cell selection 
(Leibundgut-Landmann et al., 2004). CIIta pIII is a lymphoid promoter that is 
essential for the direction of CIITA expression in B cells and plasmacytoid DCs 
(pDCs). CIIta pI is a myeloid promoter that drives the constitutive expression of 
CIITA in conventional DCs (Figure 2). 
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All isoforms of the CIITA proteins contain transcription activation domain 
on the N-terminal, a centrally located nucleotide binding domain (NBD), and a 
carboxyl C-terminal region that consists of leucine-rich repeats (LRRs) (Steimle et 
al., 2007). The NBD domains and LRRs characterise CIITA as a member of the 
CATERPILLER family, which also includes CARD4/NOD1, NOD2/CARD15, 
CIAS1, CARD7/NALP1 and NAIP, among others (Ting and Davis, 2005). The 
main function of CIITA is to provide a platform for the binding of various cis-
transcription factors such as TFIID, TFIIB, RFX, CREB and NFY, and to activate 
MHC class II and other genes transcription. Specifically, transcription-activation 
domains on the N-terminal are thought to mediate interactions with effector 
proteins that are implicated in promoting transcription, including components of 
the general transcription machinery, factors that are involved in chromatin 
remodelling, and other co-activators. In addition, the C-terminal two-thirds of the 
protein is implicated in self-association, localisation to the nucleus and 
recruitment to the enhanceosome (Reith et al., 2001; Boss and Jensen, 2003). 
2.3.1.2 DC-CIITA 
The three promoters, which do not share any sequence homology and are 
not co-regulated, give rise to CIITA transcripts with three distinct first exons and 
the shared downstream exon (Figure 1). This leads to the production of three types 
of transcripts (DC-CIITA, Type III and IV CIITA) that have different 5’ ends. 
Type IV CIITA uses the translation initiation codon in the second exon and 
translates into an 1106 amino acid protein. On the other hand, DC-CIITA and 
Type III CIITA use different initiation codons on the first exon which are both in 
frame with the initiation codon of Type IV CIITA. The use of these alternative 
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initiation codons leads to the synthesis of protein isoforms of 1207 and 1130 
amino acids, respectively (LeibundGut-Landmann1 et al, 2004).  
The DC-CIITA-specific N-terminal extension contains a unique sequence 
that shows a low similarity to CARD domain (Nickerson et al., 2001). The CARD 
domain is a homotypic protein interaction module composed of a bundle of six 
alpha helices arranged in topology homologues to the death effector domain 
(DED). The CARD domain typically associates with other CARD-containing 
proteins, forming either dimers or trimers. Even though the DC-CIITA-specific N-
terminus has a weak homology to the CARD, unlike other CARD-containing 
proteins, DC-CIITA does not interact with members of the caspase family or 
regulate apoptosis (Nickerson et al., 2001). It has also been shown that CIITA 
CARD does not activate the NF-κB promoter. However, it was found that the 
CARD-like domain specific to DC-CIITA confers a higher transactivation activity 
when compared to type III CIITA without this CARD-like domain (Nickerson et 
al., 2001).  
The elucidation of the function of the CARD-like domain (unique to DC-
CIITA) will be particularly important in the understanding of the function of DCs 
because it has been shown that CIITA expression in DCs is driven mainly by 
promoter I at the mRNA level. Moreover, DC-CIITA transcripts are by far the 
most abundant mRNA isoforms in immature bone marrow-derived DCs 
(Leibundgut-Landmann et al., 2004). Nevertheless, there has been a lack of 
research on the molecular mechanisms that underlie the function of the CARD-
like domain in CIITA. It has been hypothesised that the CIITA CARD-like 
domain may interact with a CARD of an unknown protein or proteins, possibly a 
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transcription factor or factors, or a protein that cooperates with the CIITA 
complex to enhance the transactivation of the MHC class II gene (Nickerson et al., 
2001). It will be interesting to find out more about this unknown protein or 
proteins interacting with CARD. However, the study cannot rule out the 
possibility that the higher transactivation activity of DC-CIITA can be attributed 
to more efficient nuclear translocation and increased accumulation in the nucleus. 
Therefore, a comprehensive study on the CARD domain is required for a fuller 
understanding of the function of DC-CIITA. 
2.3.2 Regulation of MHC class II by CD74 at post-translational level 
2.3.2.1 CD74 
Antigen presentation requires the help of not only MHC class II, but also 
CD74. In CD74 null mice, MHC class II molecules accumulate in the ER; then 
antigen-presenting cells lose their ability to present exogenous antigens effectively 
(Viville et al., 1993). The CD74 gene encodes a type II transmembrane 
glycoprotein that exists in several distinct forms that arise by alternative splicing 
in the mice, and by both alternative splicing and alternative translation initiation in 
the human (O'Sullivan et al., 1987). In the mouse, CD74 exists in two forms: p31 
(31kDa) and p41 (41 kDa). P31 is more abundant than p41. p41 arises by splicing 
in exon 6b, which encodes a cysteine-rich domain of 64 amino acids into the 
CD74 transcript. In humans, four CD74 gene-encoded protein products, p33, p35, 
p41 and p43, arise by two translation initiation sites within two alternatively 
spliced transcripts; p33 is the predominant protein product expressed (Ceman and 
Sant, 1995). 
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CD74 is a non-polymorphic type II integral membrane protein. Murine 
CD74 has a short (30 amino acid) N-terminal cytoplasmic tail, followed by a 
single 24-amino acid transmembrane region and a 150-amino acid-long luminal 
domain. The N-terminal cytoplasmic tail of CD74 contains two extensively 
characterised dileucine-based endosomal targeting motifs (Pond et al., 1995). As a 
result, the newly synthesised CD74 is directed into the intracellular membrane 
trafficking system, starting from the Golgi complex to end in the lysosome. 
During the journey, CD74 goes through stepwise degradation: the full-length 
CD74 (p31) is cleaved first into p22, then into p10. The p10 is further processed 
into the class II associated invariant chain peptide (CLIP), which then dissociates 
from MHC class II with the help of H2-M. H2-M facilitates the exchange of CLIP 
for the antigenic peptides (Denzin and Cresswell, 1995; Hsing and Rudensky, 
2005). The peptide-loaded MHC class II molecules then leave this compartment 
and are expressed on the cell surface and surveyed by CD4+ T cells. 
In DCs, the function of CD74 is far from being just a chaperone for the 
MHC class II. It also regulates other proteins involving in antigen presentation 
pathway. For example, the CD74 isoform, p41, binds to the active site of 
cathepsin L and permits the maintenance of a pool of mature enzymes in the 
endosomal compartments of DCs (Fiebiger et al., 2002). H2-M, which is required 
for efficient MHC class II antigenic peptide loading, is down-regulated in mature 
mouse DCs from CD74-/- mice (Pierre et al., 2000). CD74 is also required for 
CDw78 expression, which is specific for MHC class II-associated with tetraspanin 
proteins on DCs (Kropshofer et al., 2002; Poloso et al., 2006). Moreover, CD74 
alone is also able to regulate the immune response. For instance the Up-regulation 
of the CLIP peptide on mature DCs was shown to antagonise the T helper type 1 
CHAPTER 2 LITERATURE REVIEW 
21 
 
polarisation (Rohn et al., 2004). In H-2K mice, the knockdown of CD74 by siRNA 
was shown to increase significantly allogeneic lymphocyte proliferation, and to 
polarise allogeneic lymphocyte towards the Th1 response, by increasing IFN-γ 
and decreasing IL-4 production (Ke et al., 2007). CD74 is also a receptor for 
migration inhibitory factor (MIF). The binding of CD74 to MIF and then to CD44 
is known to activate extracellular signal-regulated kinase/mitogen-activated 
protein kinase (ERK/MAPK) pathway and to suppress cell apoptosis. In DCs, the 
MIF /CD74 pathway increases the antigen presentation capacity of DCs, and the 
production of IL-1β and IL-8 (Mukarami et al., 2002;Leng et al., 2003;Shi et al., 
2006). 
2.3.2.2 Regulation of CD74 expression 
The transcription regulation of CD74 was studied extensively in the 1990s. 
The regulatory mechanisms of CD74 expression share significant similarities with 
that of MHC class II. The transcriptions of both genes are under the control of 
CIITA. These genes are even required the same set of promoter elements (S box, 
X box and a modified Y box), although their translational/post-translational 
regulation pathways are different (Zhu and Jones, 1990; Tai et al., 1999). The 
degradation of MHC class II occurs via the ubiquitination pathway whereas CD74 
is degraded through stepwise proteolytses. These events involve several proteases; 
and some of them are yet to be identified. 
The use of specific protease inhibitors and murine protease gene knockouts 
has contributed to the identification of key enzymes involved in the terminal 
stages of CD74 processing (Riese and Chapman, 2000; Villadangos and Ploegh, 
2000), but the exact pathway of CD74 degradation remains unclear. The 
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endoprotease responsible for the initiation of CD74 proteolysis has not been 
identified. The initiating endoprotease has so far only been identified as a 
leupeptin-insensitive protease (Honey and Rudensky, 2003). Therefore, 
asparagine endopeptidase (AEP) was believed to be the first enzyme involved in 
CD74 degradation because of its leupeptin insensitive properties and its cleavage 
site found on CD74 (Manoury et al., 2003b). More importantly, AEP has been 
reported to initiate the degradation of CD74 in B cells (Manoury et al., 2003c). 
However, in a recent work using gene knockout mice, AEP was shown to be 
redundant because AEP-deficient mice do not exhibit significant difference from 
wild-type mice in terms of CD74 processing (Maehr et al., 2005). Becker’s study 
with brefeldin A (one of the membrane trafficking inhibitors) treatment has also 
revealed that CD74 is not a substrate of AEP but a member in the regulated 
intramembrane proteolysis (RIP) processed protein family (Becker-Herman et al., 
2005). Therefore, the endoprotease responsible for the initiation of CD74 
proteolysis still remains to be identified.  
Proteases involved in the downstream of CD74 degradation are also not 
conclusive. The use of specific protease inhibitors and gene ablation studies are 
two main methods to identify the proteases involved in the terminal stages of 
CD74 processing (Riese and Chapman, 2000; Villadangos and Ploegh, 2000). 
Experiments performed with human B cells treated with a cathepsin S inhibitor 
(Riese et al., 1996), or with cathepsin S-deficient APCs (Shi et al., 1999; 
Nakagawa et al., 1999) have shown that cathepsin S is essentially involved in 
generating CLIP in bone marrow-derived professional APCs. However, another 
study on knockout mice has indicated that it is haplotype dependant. Cathepsin S 
is only able to cleave p22 into p10 in I-Ab but not in I-Aq haploid type cathepsin S-
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deficient B cells and DCs. (Nakagawa et al., 1999; Hsing and Rudensky, 2005). 
Even in the I-Ab mouse in which cathepsin is responsible for the degradation of 
CD74, the machineries of CD74 degradation are also not well defined. Pierre and 
Mellman have shown that immature DCs, but not mature DCs, express cystatin C 
in lysosomes (Pierre and Mellman, 1998; Pierre et al., 2000). Presumably, cystatin 
C inhibits cysteine protease activity in immature DCs. This result in the 
accumulation of MHC class II–Lip10 complexes in lysosomes and consequently 
the inhibition of MHC class II–peptide trafficking to the cell surface. Moreover, 
during the maturation of DCs, the cystatin C protein level falls and the Lip10 
degradation increases. Interestingly, the cathepsin S protein level does not change. 
This implies that the control of cathepsin S activity is solely regulated by cystatin 
C protein expression. Thus, DCs may utilise the regulation of CD74 degradation 
as a mechanism to control intracellular transport and the surface expression of 
MHC class II molecules during maturation (Pierre and Mellman, 1998). However, 
the little co-localisation of cystatin C with MHC class II in both immature and 
mature DCs contradicts this hypothesis (Villadangos et al., 2001). Furthermore, 
the knockout of the cystatin C gene exerts no effect on antigen presentation (El-
Sukkari et al., 2003a). These experimental discrepancies have suggested that there 
might be other candidates involved in the degradation of CD74. 
2.4 NO regulates antigen presentation 
2.4.1 NO regulates antigen presentation 
Nitric oxide (NO) has been recognised as one of the most versatile players 
in the immune system (Bogdan, 2001). Unlike cytokines, the interaction of NO is 
not restricted to a single defined receptor; rather, it can react with many other 
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inorganic molecules (such as oxygen, superoxide or transition metals), structures 
in DNA (pyrimidine bases), prosthetic groups (such as heme) or proteins (leading 
to the S-nitrosylation of thiol groups, the nitration of tyrosine residues or the 
disruption of metal-sulphide clusters such as zinc-finger domains or iron–sulphide 
complexes) (Marshall et al., 2000). The high-output production of NO acts as a 
cytotoxic factor, inducing the apoptosis of DCs and T cells (Lu et al., 1996; Aiello 
et al., 2000). At lower concentration, NO is reported to increase the expression of 
CD1a CD80 HLA-DR during monocyte differentiation to immature DCs through 
a cyclic GMP-dependent pathway (Paolucci et al., 2003; Fernandez-Ruiz et al., 
2004). In the antigen presentation pathway, the NO is able to inhibit the activity of 
cystatin C which is involved in the regulation of CD74 (Natasa, 2006). Recent 
studies have also shown that NO remodels MHC class II trafficking by inhibiting 
caspase activity (Wong et al., 2004). The substrates of caspases in DCs include γ -
adaptin and α-adaptin, which belong to adaptor protein-1 (AP-1) complex and AP-
2 complexe, respectively. During maturation, the decrease of caspase activity 
accompanies the increase of the intact forms of α- and γ-adaptin. This implies that 
the accumulation of AP-1 and AP-2 enhances the cell surface expression of MHC 
class II. However, the silencing of both AP-1 and AP-2 in DCs or Hela-CIITA 
cells does not alter MHC class II cell surface expression (Santambrogio et al., 
2005). Moreover, the speed of clathrin-mediated endocytosis is unaltered in 
mature DCs (Delamarre et al., 2005). These inconsistencies suggest that NO and 
caspase might interact with other antigen-presenting-related proteins besides 
membrane trafficking-related molecules.  
The trafficking of MHC class II in DCs is multidirectional and reversible. 
The newly synthesised MHC class II can be directed to the trans-Golgi network 
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(TGN) or plasma membrane. MHC class II, which arrives on the plasma 
membrane, can even be retrieved back to early endosomes and recycled back to 
the plasma membrane. Therefore, besides α-adaptin and γ-adaptin, it is possible 
that the regulation of MHC class II trafficking requires other endosomal proteins 
such as syntaxins, dynamins, Vti1a and Vti1b. Furthermore, it is also critical as a 
“balancing act” amongst these trafficking related molecules in order to maintain a 
proper distribution of MHC class II. Previous studies have shown that NO 
regulates the expression of these proteins. Therefore, NO may be one of the key 
molecules regulating MHC class II trafficking and antigen presentation in DCs 
(Villadangos, et al 2005, Wong et al, 2006). 
2.4.2 The source of NO 
NO is synthesised by nitric oxide synthase (NOS). NOS catalyses a five 
electron oxidation of a guanidine nitrogens of L-arginine to produce NO and 
cirtulline as by-product. NG-monomethyl-L-arginine (L-NMMA) and other NG-
substituted-L-arginine derivatives competitively inhibit the NO synthases (David 
and Timothy, 2008). 
There are three distinct isoforms of NOS: NOS1, NOS3 and NOS2. NOS1 
is also called neuronal NOS (nNOS), which is predominantly expressed in 
neuronal cells, skeletal muscle cells and cardiac muscle cells (Kishimoto, et al, 
1992, Hall, et al, 1996). NOS3 or endothelial NOS (eNOS) mainly expresses in 
endothelial cells, cardiac myocytes and blood platelets (Schuman and Madison, 
1991). Both NOS1 and NOS3 are constitutively expressed. The third NOS enzyme, 
NOS2 or inducible NOS (iNOS) is contrasted with the other two NOS isoforms in 
several aspects. First, a plethora of human cells have been shown to express NOS2 
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including all of antigen presenting cells such as B cells, macrophages and 
dendritic cells. Second, the expression of NOS2 is not constitutive but is inducible 
by various cytokines, and microbial products, for example LPS. Third the activity 
of NOS2 is independent on calcium, which is critical for the activity of NOS1 and 
NOS3 (David and Timothy, 1998).  
In DCs, the production of NO is highly dependent on NOS2 (Lu et al., 
1996). In immature DCs, both mRNA and protein levels of NOS2 are very low. 
And the amount of NO is also nearly undetectable. After DCs are stimulated to 
undergo maturation with IFN-γ or LPS in vitro, NOS2 mRNA and protein 
expression levels are up-regulated drastically and at the same time, NO is 
produced in large amount.  
To fully understand the biological functions of NO in the immune system, 
the use of the NO-donor as an exogenous source of NO is essential. Currently, 
there are three groups of NO donors that are used in pre-clinical studies and 
clinical trials. These are sodium nitroprusside (SNP), diaseniumdiolates 
(NONOate) and S-nitrosothiols (Lu et al., 1996; Miller and Megson, 2007). 
Compared with the other two NO donor, NONOate is more popular in most 
experimental settings due to the predictable nature of NO release. Its ionic forms 
have reproducible rates of spontaneous NO generation at a physiological pH. Thus, 
we have chosen to use NONOate in this study (King, 2005).  
2.5 Summary and the importance of this study 
In summary, CIITA, CD74 and NO are all important molecules in the antigen 
presentation pathway. However, several key details about these molecules remain 
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poorly understood. (1) CIITA is essential for the expression of MHC class II, 
CD74 and H2-M in several APCs. In DCs, the major form of CIITA is the DC-
CIITA isoform which contains an additional CARD-like domain. The function of 
this domain still remains unknown. (2) CD74 directs the folding, trafficking and 
functioning of MHC class II by a stepwise degradation pathway. This pathway 
was believed to be under the control of the cystatin C and cathepsin pathway. 
However, the possibility of the existence of other pathways cannot be excluded 
due to inconsistent experimental data as has been earlier reviewed. (3) NO is also 
involved in the antigen presentation pathway by modifying cystatin and caspase 
activities. However, direct evidence of NO regulating antigen presentation in DCs 
is still lacking. Addressing the above gaps mentioned will provide insights into the 
MHC class II antigen presentation pathway of DCs, and eventually lead to a novel 











Figure 5: Summary of gaps on the studies of antigen presentation in DCs, 
which was investigated in this project 
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3.1 MATERIALS AND METHODS 
3.1.1 Mice 
C57/BL 6J (I-Ab, I-Eb) and BALB/c (I-Ad, I-Ed) mice were purchased from 
centre for Animal Resources, Singapore. All protocols on mice are conducted 
under the Institutional Animal Care and Use Committee (IACUC), National 
University of Singapore. 
3.1.2  Cell lines and cell culture medium 
Dendritic cell line, DC2.4, was kindly provided by Dr. Kenneth Rock 
(University of Massachusetts Medical Centre, Worcester, USA). DC2.4 cells were 
generated from C57/BL 6J mouse bone marrow culture. And the cells were 
immortalised by transducing GM-CSF and by supertransfecting with myc and raf 
oncogenes. DC2.4 cells displayed dendritic morphology, and expressed the 
dendritic cell-specific markers CD205 as well as high levels of MHC molecules 
and costimulatory molecules (Shen et al. 1997).  
Human epithelial carcinoma cell line, A431, was obtained from the 
American Type Culture Collection (ATCC) (Manassas, USA). A431 cells were 
established from an epidermoid carcinoma in the vulva of an 85 year old female 
patient, and it is a model cell line used in biomedical research. Dulbecco’s 
Minimal Eagles medium (DMEM), Opti-MEM, fetal bovine serum (FBS), MEM 
non-essential amino acids and Effectene transfection reagents were purchased 
from Invitrogen (Carlsbad, USA). Tissue culture flasks, plates, dishes and other 
disposables were purchased from Nunc (Rochester, USA).  
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3.1.3  Antibodies and reagents 
Lipopolysaccharide (LPS), E. coli, caspase inhibitors and chromatic 
caspase activity kit were purchased from Calbiochem (Darmstadt, Germany). 
Granulocyte/Macrophage colony stimulating factors (GM-CSF) were purchased 
from R&D Systems (Minneapolis, USA). Greiess reagent and Tetramethyl 
benzidine (TMB) were purchased from Sigma-Aldrich (St. Louis, USA). Ficoll-
paque plus was purchased from GE Healthcare (Bjőrkgatan, Sweden). Other 
chemical reagents which are not mentioned here are all purchased from Sigma-
Aldrich (St. Louis, USA). 
Protein A and protein G coupled sepharose beads were purchased from 
Amersham Biosciences (Buckinghamshire, UK). Reduced glutathione and 
glutathione agarose beads were purchased from Sigma-Aldrich (St. Louis, USA). 
QIAquick gel extraction Kit, Miniprep DNA Purification Kit and Maxi 
DNA Purification Kit were purchased from Qiagen (Hilden, Germany).  
Restriction enzymes, T4 DNA ligase, Taq DNA polymerase, Pfu DNA 
polymerase, M-MLV reverse transcriptase, and calf intestine alkaline phosphatase 
(CIP) were purchased from Promega (Madison USA). 4',6-Diamidine-2'-
phenylindole dihydrochloride (DAPI) was purchased from Vector Laboratories 
(Burlingame, USA).  
The primary antibodies used in this study are summarised in table 2. The 
various goat anti-mouse/anti-rabbit immunoglobulin conjugated to either 
fluorescein isothiocyanate (FITC), cyanine dyes 3 (Cy3) or rhodamine which were 
using in immunofluorescence staining were purchased from Jackson 
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Immunoresearch Laboratories (West Grove, USA). The corresponding IgG for 
isotype control were purchased from BD Biosciences (San Jose, USA).  
The secondary antibodies, i.e. goat anti-mouse / anti-rabbit antibodies 
(HRP-conjugated) and nitrocellulose membrane were purchased from Amersham 
Biosciences (Buckinghamshire, UK). West Pico Supersignal substrate/enhancer 
was purchased from Perice Chemical (Rockford, USA). 
Table 2: Antibodies used in DC-CASPIC study 
Antibody Isotype Clone name Format Company 
C-myc Mouse IgG1 9E10 -- EMD Biosciences, Inc. Calbiochem, USA 
NOS2 Mouse IgG1 2 -- BD Biosciences, San Jose, USA 
NOS2 Rabbit IgG Polyclonal -- BD Biosciences, San Jose, USA 
NOS3 Mouse IgG1 3 -- BD Biosciences, San Jose, USA 
I-A/I-E Mouse IgG2b M5/114.15.2 -- BD Biosciences, San Jose, USA 
Cytochrome c Mouse IgG2b 7H8 -- Santa Cruz Biotechnology Inc., Cruz, USA 
β-actin Mouse IgG1 AC15 -- Sigma-Aldrich, Inc. USA 
c-myc Rabbit IgG Polyclonal -- Santa Cruz Biotechnology Inc., Cruz, USA 
Caspase 1 Rabbit IgG Polyclonal -- Santa Cruz Biotechnology Inc., Cruz, USA 
Caspase 3 Rabbit IgG Polyclonal -- Santa Cruz Biotechnology Inc., Cruz, USA 
Caspase 11 Goat IgG Polyclonal -- BD Biosciences, San Jose, USA 
GST Rabbit IgG Polyclonal -- Santa Cruz Biotechnology Inc., Cruz, USA 
CD11c Hamster IgG1 HL3 FITC BD Biosciences, San Jose, USA 
CD80 Mouse IgG1 L307.4 FITC BD Biosciences, San Jose, USA 
CD86 Mouse IgG1 FUN-1 FITC BD Biosciences, San Jose, USA 
I-Ab Mouse IgG2a 25-9-17 FITC BD Biosciences, San Jose, USA 
3.1.4 Culture of DCs 
C57/BL 6J mice (I-Ab, I-Eb) were sacrificed by CO2 and sterilised by 
soaking into 70% ethanol for one minute. After peeling away the fur by forceps, 
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the hand legs were cut out and put into plain DMEM and the muscles were 
scraped off by forceps and blades. Before filtering with 70 μM mesh nylon screen, 
the hematopoietic stem cells were flushed out from the resulting long bones with 
21 G needle and 1 mL syringe into DMEM supplemented with 5% FBS 
containing 20 ng/mL of GM-CSF. Then cell number and viability were examined 
by hemocytometer and trypan blue stain before seeding into cell culture dishes. 
On day 2, 4 and 5, half of volume of old DMEM medium was replaced with same 
volume of fresh complete DMEM medium with 15 ng/mL of GM-CSF. The 
immature DCs were harvest in day 7 by flushing out with blue tips or by 5 μM 
EDTA. To induce cell maturation, the day five cells were further subcultured in 
DMEM supplemented with 1 μg/mL LPS (Sigma-Aldrich, St. Louis, USA) for 40 
– 48 hours.   
3.1.5 Isolation of thymocyte  
BALB/c mice were sacrificed by CO2 and sterilised by soaking into 70% 
ethanol for one minute. Freshly removed thymus was placed in 60 × 15 Petri 
dishes containing 3 mL complete DMEM. Using a circular motion, the thymus 
was pressed against the bottom of the Petri dish with the plunger of 5 mL syringe 
until mostly fibrous tissue remained. Clumps in the suspension were further 
dispersed by drawing up and expelling the suspension several times through a 5 
mL syringe equipped with a 19 G needle. Suspension was expelled into a 
centrifuge tube through a 200 μM mesh nylon screen. After washing one time with 
complete DMEM, the cells were resuspended into 16 mL complete DMEM. Six 
milliliter Ficoll paque phase was layered under the cell suspension carefully 
followed by centrifugation for centrifuge 15 minutes at 800 g at room temperature. 
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No brake was used in centrifugation. Monocyte cells floating on top of the high-
density solution were isolated by moving pipette tip over the surface of high-
density layer and by drawing cells up in a 5 mL pipette. Monocytes were 
transferred into another tube and washed twice with complete DMEM. Then cell 
number and viability were examined by hemocytometer and trypan blue stain 
before seeding into cell culture dishes. Cells were seeded into 24-well plate with a 
cell density of 3 × 106 cells/well and were maintained in the DMEM medium 
supplemented with 50 ng/mL of IL-2. 
3.1.6 Culture of cell lines 
DC2.4 and A431cells were maintained in DMEM supplemented with 10% 
FBS, antibiotics and L-Glutamine (Invitrogen, Carlsbad, USA). The mammalian 
expression vectors used was pDMyc which was modified pCINeo vector with two 
copies of Myc tag at the 5’ end. Cells were plated into plates or dishes and grown 
for 24 hours to a confluency of 50−60%. Lipofectamine 2000 (Invitrogen, 
Carlsbad, USA) and Effectene (Invitrogen, Carlsbad, USA) were used as 
transfection reagents for DC2.4 cells and A431 cells, respectively, according to 
the manufacturers’ instructions. Cells were harvested for microscopic examination 
20 hours after transfection. DC2.4 cells are mainly for the study of function of 
DCs; And A431 cells are for protein localisation studies. 
3.1.7 Phagocytosis assay 
The phagocytosis assay was based on the Phagocytosis Assay Kit (Vybrant, 
Carlsbad, USA), with 3 modifications made to the protocol: First, 100μl of K12 
fluorescence E. coli bioparticles was mixed with 100μl of medium to provide the 
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cells better conditions for engulfment. Second, the phagocytosis incubation time 
was reduced from 3 hr to 2 hours to avoid the phagocytic activities of cells to be 
compared from reaching a plateau phase. Third, quenching time was doubled from 
1 minute to 2 minutes to ensure extracellular particles were sufficiently quenched. 
Cells seeded into a 96-well ELISA plate at a concentration of 1×105 to 2×105 
cells/well were allowed to adhere for 4 hr to the bottom of the well, after which 
the fluorescence-conjugated E. coli bioparticles were added and phagocytosis was 
allowed to proceed for 2 hr. The bioparticles were removed and Trypan Blue was 
added for 2 min to quench extracellular bioparticles. The Trypan Blue was then 
removed and the amount of bioparticles engulfed by the cells was quantitatively 
measured using either SpectraMax Gemini EM ELISA plate reader at 480 nm 
excitation and 520 nm emission or Tecan GENios ELISA plate reader at 485 nm 
excitation and 535 nm emission. 
3.1.8 Molecular cloning 
The DNA fragment to be cloned into a specific vector was either amplified 
by polymerase chain reaction (PCR) or restriction digested from another plasmid 
DNA. The sequences of the primers used for PCR normally included the sequence 
recognised by specific restriction enzymes selected for the cloning. Ten 
microgram of vectors were typically digested overnight at 37 °C by one unit of 
restriction enzymes and dephosphorylated by one unit of calf intestinal 
phosphatase for 45 minutes at 37 °C. One unit of ligation was performed using T4 
DNA ligase, with the ligation mixture incubated overnight at 4 °C. 
Transformation was then carried out by incubating the ligation mixture with E. 
coli DH5α competent cells on ice for 30 minutes. Cells were then heat-shocked 
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for one minute in a 42 °C water bath. Lysogeny broth (LB) was then added to the 
cells and the cells were incubated for 45 minutes at 37 °C for recovery. The cells 
were then plated out onto LB plates supplemented with 100 mg/mL ampicillin and 
incubated at 37 oC overnight. Recombinant clones were verified by automated 
sequencing. 
3.1.9 Reverse transcription 
Total RNA was extracted from cells using Trizol reagent (Invitrogen, 
Carlsbad, USA) according to manufacturer’s instructions. Total RNA was then 
recovered by precipitation with isopropyl alcohol. Synthesis of cDNA from 
mRNA transcripts was performed using the following: 3 μg RNA, 1.5 μg oligo 
(dT) in a reaction volume of 25 μL. Samples were heated at 70°C for 5 minutes, 
placed on ice immediately and then treated with 0.5 μL RNase inhibitor, 5 μL 
MLV-RT buffer, 10 mM dNTP, followed by incubation at 42 °C for two minutes. 
After a pulse spin, 2 unit of MLV reverse transcriptase was then added to the 
samples and were incubated at 42 °C for 90 minutes. After the incubation, 
samples were heated to 70 °C for five minutes and then stored at -20 °C.  
3.1.10 PCR-based deletion mutagenesis 
DC-CIITA recombinant plasmids were used as templates for mutagenesis. 
Template-specific mutagenic primers were designed for the PCR-based deletion 
mutagenesis, as shown in Table 3. Briefly, a 50 μL reaction system containing 5–
50 ng wild-type plasmid, 0.25 μM of sense and antisense mutagenic primers 
respectively, 0.2 μM dNTPs and 2.5 unit of Pfu DNA polymerase was subjected to 
16 thermal cycles (95 °C for one minute, 55 °C for one minute, and 72 °C for six 
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minutes; final extension at 72 °C for 20 minutes). Fifteen microliter of the PCR 
products were then digested with one unit of corresponding restriction enzymes 
and ligated unto respective vectors followed by transformation into E.coli DH5α 
competent cells by heat shock. The mutant sequences were then verified by 
automated DNA sequencing. 
Table 3: Primers used in DC-CASPIC study 





Sense   5’ GGAGAATTCAATGAACCACTTCCAGGCCATCCTG 3’ 




Sense    5’ GGAGAATTCAATGAACCACTTCCAGGCCATCCTG 3’ 
Antisense  5’ GCTCTAGAGGTCACTCTTCTTCCAGCAGGCC 3’ 
 
DC-CASPIC(1-69) Sense         5’ GGAGAATTCAATGAACCACTTCCAGGCCATCCTG 3’ 





Sense         5’ GGAGAATTCAATGAACCACTTCCAGGCCATCCTG 3’ 
Antisense  5’ GCTCTAGAGGTCAAACTCCATGGTCCCTGTAGC 3’ 
 
GST-CARD Sense         5’ GCGCGGATCCGCGAACCACTTCCAGGCCATCCTG 3’ 
Antisense  5’ GCCGGAATTCCGTCAGTCCCTGTAGCTGGTG 3’ 
 
3.1.11 Automated DNA sequencing 
The ABI PRISM BigDye terminator cycle sequencing ready reaction kit 
(Applied Biosystems, Foster, USA) was used for automated cycle sequencing. 
Recombinant plasmid DNA was first extracted from liquid bacterial culture using 
Miniprep DNA purification kit as described earlier. Subsequently, a reaction 
system of 20 μL consisting of 2μL BigDye terminators, 3.2pmol of either forward 
or reverse sequencing primer, 2μL of purified plasmid DNA template, and 3 μL of 
5 × reaction buffer (400 mM Tris-HCl (pH 9.0), 10 mM MgCl2) was subjected to 
35 thermal cycles (95 °C one minute, 58 °C one minute, and 72 °C one minute; 
final extension at 72 °C for five minutes). The extension products were then 
precipitated with 80 μL of ethanol-sodium acetate solution (consisting of 3 μL of 3 
M sodium acetate, pH 4.6, 62.5 μL of non-denatured 95% (v/v) ethanol, and 14.5 
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μL of deionised water) for 15 minutes at room temperature. After centrifugation at 
13,000 rpm for 20 minutes, the DNA pellet was wash twice with 70% (v/v) 
ethanol, with an incubation time of 5−15 minutes each time followed by 
centrifugation at 13,000 rpm for 10 minutes. The DNA pellet was allowed to dry 
and was resuspended in 170 μL of Hi-Di Formamide. The resuspended DNA was 
heated at 95 ºC for two minutes to denature the DNA strands and was then 
immediately placed on ice. Ten microliter of the DNA was dispensed into a 96-
well microtiter place and sent to ABI PRISM® 3100 DNA Sequencer (Applied 
Biosystems, Foster, USA) for automated DNA sequencing. The sequencing results 
were viewed and analysed by the software Vector NTI (Invitrogen, Carlsbad, 
USA). 
3.1.12 Large-scale production of GST-tagged recombinant protein  
Glutathione S-transferase (GST)-tagged DNA constructs (in pGEX/KG 
vectors, Pharmacia) were transformed into E.coli BL21 competent (DE3) cells. 
Two hundred millilitre of bacterial culture in LB medium supplemented with 100 
mg/mL ampicillin was grown overnight with shaking at 37 °C. On the next day, 
600 mL fresh medium was added to the culture and cells were allowed to grow for 
another 2−3 hours until OD600nm reached 0.6. Protein expression was induced by 
adding isopropyl-β-D-thiogalactopyranoside (IPTG) at a final concentration of 0.1 
mM. The culture was then allowed to grow for another 3−4 hours before 
harvesting by centrifugation for 5−10 minutes at 2,500 g. The pellets were 
resuspended in the appropriate volume of PBS and phenylmethylsulfonyl fluoride 
(PMSF) (a general protease inhibitor). Sonication was carried out at power setting 
of 7 (Misonix, Farmingdale, USA), with 4 pulses lasting 10 sec each with 15 sec 
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rest period between pulses. The lysed cells were then centrifuged at 20,000 g for 
30 minutes, and supernatant was collected. Glutathione agarose beads were then 
added to the supernatant and binding was carried out at 4 °C with constant mixing 
on a roller for two hours or overnight. The beads with bound protein were then 
transferred into a disposable chromatographic column. After extensive washing of 
the beads, the GST-tagged protein was eluted with glutathione (20 mM in 0.1% 
(v/v) Triton-X100, 50 mM Tris in PBS). The eluted fractions were analysed for 
the presence of GST-tagged protein by SDS-PAGE and coomassie blue staining. 
Fractions containing GST- tagged protein were pooled, and dialysed in cold PBS 
before they were aliquoted and kept frozen at -20 °C. 
3.1.13  Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
SDS-PAGE gels were cast with the Bio-Rad miniprotein III gel casting 
system. The resolving gel contained different percentages of 
acrylamide/bisacylamide mixture (30% with a ratio of 29:1) in 0.375 M Tris-Cl, 
pH 8.8 and 0.1% (w/v) SDS. The stacking gel contained 4% (v/v) 
acrylamide/bisacylamide in 0.125 M Tris-Cl, pH 6.8 and 0.1% (w/v) SDS. 
Polymerisation was induced by the addition of ammonium persulfate (APS) and 
N,N,N,N,-Tetramethyl-Ethylenediamine (TEMED). Protein samples were 
dissolved in SDS sample buffer (50 mM Tris-Cl, pH 6.8, 2% (w/v) SDS, 100 mM 
dithiothreitol (DTT), 10% (v/v) glycerol and 0.1% (v/v) bromophenol blue) and 
loaded onto the gel. Gel electrophoresis was typically carried out in Tris-glycine 
buffer (0.3% (w/v) Tris-base, 1.4% w/v glycine and 0.1% (w/v) SDS) at a 
constant voltage of 100 V. 
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3.1.14  Western blot analysis 
The proteins to be identified were subjected to SDS-PAGE separation and 
the separated proteins were then transferred onto nitrocellulose membrane. The 
transfer was carried out in transfer buffer (0.3% (w/v) Tris-base and 1.4% (w/v) 
glycine) with a Bio-Rad wet transfer apparatus (Bio-Rad Kaboratories, Miami 
USA) at constant voltage of 100 V for one hour. The membrane was then blocked 
in 5% (w/v) skim milk followed by incubations with specific primary antibodies 
and appropriate secondary antibodies conjugated to horse radish peroxidase (HRP) 
diluted in 5% (w/v) skim milk. Membranes were washed three times with PBS + 
0.05% (v/v) Tween 20 after each antibody incubation steps. Immunoreactive 
signals were visualised using a chemiluminescent substrate (West Pico 
supersignal kit, Pierce, Rockford USA) and X-ray films, which were developed 
using a Kodak X-ray film processor (Rochester, USA). 
3.1.15  GST pull down  
GST pull down of tissue lysates was used either to screen for novel 
interacting proteins for the GST-CARD (large-scale) or to perform interaction 
analysis (small-scale). In a typical large-scale GST pull down experiment, 50−100 
mg of tissue lysate in 150 mM NaCl, 20 mM Tris-HCl, pH 7.4, 2 mM EDTA, 2 
mM DTT, 1% (v/v) Triton X-100, and a cocktail of protease inhibitors was 
incubated with 50−100 µg of GST protein (used as negative control) or GST-
tagged protein (protein of interest)-bound glutathione sepharose beads. The 
incubation was conducted at 4 °C with rolling for two hours or overnight. Beads 
were then washed twice with extraction buffer containing 0.5% (v/v) Triton X-100, 
twice with extraction buffer containing 0.1% (v/v) Triton X-100, and once with 
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extraction buffer without Triton X-100. Bound proteins were then eluted with 
SDS sample buffer and subjected to SDS-PAGE analyses.  
In a typical analytical GST pull down experiment, 2 mg of protein lysate 
(with Triton-X100 concentration diluted to 0.2% (v/v) with PBS) was incubated 
with 10−20 μg of GST protein (used as negative control) or GST-tagged protein 
(protein of interest)-bound glutathione sepharose beads. Elution and SDS-PAGE 
separation were performed as described for the large-scale GST pull down above. 
Separated proteins were then subjected to Western blot analysis. 
3.1.16  Immunoprecipitation 
Proteins were extracted from cells and incubated on ice for one hour in 
cold lysis buffer (20 mM Tris [pH 8.0], 10 mM EDTA, 100 mM NaCl, 1 mM 
DTT, 1% (v/v) Brij 98, a polyoxyethylene ether followed by centrifugation at 
13,000 rpm for 15 minutes at 4 oC. Protein exacts (1 mg) were incubated 
overnight with 5 μg of the corresponding antibodies bound to protein G Sepharose 
beads (Pharmacia) in lysis buffer plus 1% (w/v) BSA and 10% (v/v) FBS at 4 oC. 
Beads were then washed three times in Buffer A (20 mM HEPES, [pH 7.2], 100 
mM KCl, 1 mM DTT, 10 mM EDTA, 0.2 mM ATP, 0.5% (v/v) Brij98) and three 
times in Buffer B (identical to Buffer A except without Brij98) before being 
resuspended in SDS sample buffer. Immunoprecipitated proteins and 5% of total 
the supernatant were separated on SDS-PAGE and analysed by Western blot. 
3.1.17 Isolation of mitochondria 
Cells were harvested with PBS by using cell scraper. The supernatant was 
resuspended in 3 mL of ice-cold IBc buffer (10 mM Tris 1 mM EGTA 200 mM 
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sucrose, 10 mM MOPS pH 7.4) after washing one time with PBS. The cells were 
homogenised with 30−40 strokes using a Teflon pestle operated at 1,600 r.p.m. 
The homogenate was then transferred to a 50 mL polypropylene Falcon tube and 
centrifuged at 600 g for ten minutes at 4 °C. The supernatant was collected and 
transfered to a glass centrifuge tube followed by centrifugation at 7,000 g for ten 
minutes at 4 °C. The supernatant was then discarded and the pellet was washed 
with 200 μL of ice-cold IBc buffer. The pellet was resuspended in 200 μL of ice-
cold IBc buffer and transfered the suspension to a 1.5 mL microfuge tube followed 
by centrifugation at 7,000 g for ten minutes at 4 °C. The pellet containing 
mitochondria was collected, resuspended in IBc buffer, and kept on ice. 
3.1.18 Methanol fixation and immunofluorescence staining 
Cells grown on coverglasses were fixed in pre-chilled methanol for four 
minutes at -20 oC then transferred to room temperature for two minutes. The 
coverglasses were then washed (with rocking for 2−3 minutes) four times with 
PBS. The coverglasses were then incubated with primary antibody followed by 
secondary antibody for about one hour each at room temperature. Non-specific 
binding was removed by washing (with rocking for 2−3 minutes) three times with 
PBS. The coverglasses were then incubated with primary antibody followed by 
secondary antibody (conjugated to fluorophore FITC or Texas-Red) diluted in 
staining buffer (5% (w/v) BSA, 2 mM EDTA, 10% (w/v) goat serum in PBS). 
Non-specific binding was removed by washing (with rocking for 2−3 minutes) 
three times with PBS supplemented with 1% (w/v) saponin. The coverglasses 
were finally mounted onto glass slides with one drop of Vectashield mounting 
medium. The edges of the coverglass were sealed with nail polish and the slides 
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were then ready for viewing under a fluorescence microscope. The confocal 
images were taken using either Olympus Fluoview 500 microscope with Fluoview 
version 5.0 software (Tokyo, Japan).  
3.1.19 Immunogold electron immunohistochemistry  
DC2.4 cells grown on φ 100 mm dishes were fixed with 4% (v/v) 
paraformaldehyde for three hours at room temperature. The cells were scraped out 
and washed twice with PBS. Then the cells were dehydrated by going through 
25%, 500%, 75%, 95% and 100% (v/v) (two changes) ethanol followed by 
infiltration with L.R. White embedding medium for two days. After embedding at 
50 oC for 48 hours, the blocks were cut into sections with thickness of 100nm. 
Sections were blocked with 5% (w/v) BSA in PBS, then incubated with rabbit 
polyclonal anti-mouse NOS3 antibody (1:10) and mouse anti-mouse cytochrome c 
antibody (1:10) for one hour followed by incubation with a goat anti-rabbit gold 
(15 nm)-conjugated IgG (1:20) and goat anti-mouse gold (5 nm)-conjugated IgG 
(1:20) (Sigma, St. Louis, USA). Sections were contrasted with uranyl acetate, and 
viewed under electron microscopy EMS208 PHILIPS (Hillsboro, USA). Negative 
controls were carried out by omitting primary antibodies. 
3.1.20  Flow cytometry analysis 
Cells were harvested with PBS supplemented with 2 mM EDTA, then 
washed once with staining buffer (5% (w/v) BSA, 2 mM EDTA, 2 mM NaN3 in 
PBS) followed by incubation for 30 minutes on ice with the FITC-conjugated 
antibody. For intracellular staining, cells were fixed and permeabilised with pre-
chilled methanol for two minutes, then incubated with primary antibody followed 
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by PE conjugated anti-rabbit IgG. After washing with staining buffer, cells were 
fixed with 1% (w/v) paraformaldehyde and the immunophenotypic analysis was 
performed on a FASCAN flow cytometry (DAKO, Glostrup, 
Denmark). 
3.1.21 Quantification of NO 
NO was assayed by measuring the concentration of stable end product 
NO2-. NO2- production was determined by Griess reaction. Aliquots of culture 
supernatant (100 μL) were incubated with 100 μL of Griess reagent (Sigma, St. 
Louis, USA) at room temperature for ten minutes. The absorbance at 550 nm was 
then measured in an automated plate reader. NO concentration was determined 
with reference to a NaNO2 standard curve. 
3.1.22 Caspase activity assay 
Ten million cells were lysed with 1mL lysis buffer (50 mM HEPES, 5 mM 
DTT, 0.1 mM EDTA, 0.1% (v/v) CHAPS, pH 7.4) for four minutes at 4 oC. 
Twenty microgram of protein was incubated at 37 °C in a buffer containing 25 
mM HEPES (pH 7.5), 10% (w/v) sucrose, 0.1% (v/v) CHAPS and 10 mM DTT, 
with the respective colourimetric substrates [caspase 1 substrate VI (Z-YVAD-
pNA), caspase 2 substrate I (Z-VDVAD-pNA), caspase 3 substrate IV (Ac-
DEVD- pNA), caspase-4 substrate II (Ac-LEVD-pNA)] (all from Calbiochem, 
Darmstadt, Germany), in a 96-well, flat-bottom microtiterplate. The cleavage of 
the substrates was quantified by spectrophotometric detection of free pNA (λ = 
400 nm) after cleavage from the caspase peptide substrates after two hours. 
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3.1.23 Statistics 
Two tail-student's t-test was used for statistical analyses. 
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3.2 RESULTS 
3.2.1 Characterisation of cultured DCs 
Bone marrow-derived cells from C57BL/6J mice were cultured in 10mm 
diameter dishes for five days in complete DMEM medium with 20 ng/mL GM-
CSF, and the resulting cells were flushed out from dishes, and then examined by 
flow cytometry with FITC-conjugated CD11c and MHC class II antibodies. The 
results showed that 79.34% of the cells were CD11c positive (Figure 6A, C), 
whereas only 18.56% of the cells were MHC class II positive (Figure 6B). A low 
cell surface MHC class II expression is expected in immature DCs. Moreover, the 
size and morphology of these cells under immunofluorescence microscopy are 
also similar to typical immature DC phenotypes which exhibit smooth edges and 
fewer dendrites compared with mature DCs (Figure 6C, 7B). These results 
indicate that the majority of isolated cells displayed typical characteristics of 
immature DCs. 
After induction with pathogen-related molecules such as LPS, immature DCs 
undergo a series of distinct changes including the formation of dendrites, an 
accumulation of cell surface MHC class II expression, an escalation of NO 
production and decrement of phagocytosis and macropinocytosis (Trombetta et al., 
2005). These phenotypic changes mark the maturation of DCs. To verify whether 
the mouse bone marrow-derived DCs are induced by LPS to become mature DCs, 
a series of experiments were carried out to identify any phenotypic changes. First, 
cellular distribution of MHC class II was studied. As shown in Figure 7A and C, 
before LPS induction, most MHC class II molecules were localised in the  
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Figure 6: Culture of DCs 
(A-B) Cells isolated from mouse bone marrow were cultured with 20 ng/mL GM-CSF for five days in vitro and stained with FITC-conjugated 
CD11c (Isotype: hamster IgG1, Clone: HL3) (A) and MHC class II antibodies (Isotype: mouse IgG2a, Clone: 25-9-17)  (B). Stained DCs were 
analysed with flow cytometry and control staining (red histogram) was performed with the corresponding isotype (hamster IgG1 for CD11c 
staining) and mouse IgG2b for MHC class II staining). (C). The isolated cells were also fixed and stained with CD11c antibody (green) and DAPI 
(blue) and evaluated under fluorescent microscope. 






Figure 7: Redistribution of MHC class II during maturation of DCs 
(A-B) Immature DCs were either untreated (control) or treated with 1 μg/mL LPS 
for 48 hours, and both were stained with FITC-conjugated anti-MHC class II 
antibodies (Isotype: mouse IgG2a, Clone: 25-9-17) . Stained immature and mature 
DCs were analysed by flow cytometry. Control staining (red histograms) was 
performed with the corresponding isotype, mouse IgG2b (C-D) immature and 
mature DCs were cultured on coverslip and stained with MHC class II-FITC 
antibody (green) and DAPI (blue). The cells were then evaluated under 
fluorescence microscope. 
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endosomal/lysosomal-like-structure with flow cytometry and immunofluorescence 
microscopy. This observation is consistent with previous studies which showed 
that MHC class II molecules of immature DCs are retained in lysosomes and 
antigen presenting compartments (Trombetta et al., 2005), and after maturation, 
these intracellular MHC class II molecules are found on the plasma membrane. By 
regulating MHC class II transport and compartmentalisation, mature DCs are able 
to present antigens to cell surface, which are taken up and processed in endosomes 
and lysosomes. (Pierre and Mellman, 1998; Turley et al., 2000). Accordingly, our 
results showed that LPS-induced bone marrow-derived DCs expressed a higher 
amount of cell surface MHC class II molecules (Figure 7B, D). In addition, the 
LPS-induced DCs exhibited more dendrites than those without LPS induction on 
under microscopy (Figure 7D). Next, the phagocytic activity of the isolated DCs 
was monitored using Vybrant Phagocytosis Assay Kit. As shown in Figure 8, the 
phagocytic activity decreased nine folds in LPS-induced DCs (p < 0.01). Lastly, 
NO production was monitored. NO level was increased by 8.28 folds upon LPS 
induction (p < 0.01) (Figure 9). Taken together, our results suggest that the mouse 
bone marrow-derived DCs were immature DCs and that LPS stimulation 
developed them into mature DCs. 
3.2.2 Elucidation of new isoform of DC-CIITA 
As an initial step to study the regulation of antigen presentation in DCs, 
the function of the CARD-like domain on DC-CIITA was investigated. The 
cDNA fragment encoding the CARD-like domain of mouse DC-CIITA was 
amplified by reverse transcription PCR (RT-PCR) (Figure 10) using total RNA 
prepared from untreated (Figure 10 Ctrl, lane 1) and LPS-treated DCs (Figure 10  






Figure 8: Inhibition of phagocytosis during maturation of DCs 
Immature DCs were either untreated (Control) or treated with 1 μg/mL LPS for 48 
hours and subjected to a phagocytosis assay. A fluorescent reading was taken, 
using a Tecan GENios ELISA plate reader (Männedorf, Switzerland). Data shown 
here are the mean ± s.d. from three independent cultures. (**, p < 0.01) 






Figure 9: Increase in NO production during maturation of DCs 
Immature DCs were either untreated (control) or treated with 1 μg/mL LPS for 48 
hours. NO2- produced in the medium was qualified with Griess assay. Data shown 
here are the means ± s.d. from three independent cultures. (**, p < 0.01) 
 
 






Figure 10: RT-PCR results showing a new isoform of DC-CIITA 
(A) Reverse transcription-PCR was performed using immature (upper 
panel, lane 1) and mature DCs (upper panel, lane 2) to amplify the DNA fragment 
encoding the CARD-like domain of DC-CIITA. (B) The bars represent the 
densities of DC-CASPIC and DC-CIITA bands (normalised to β-actin bands). 
Data shown here are the mean ± s.d. from three independent cultures. For the 
convenience of presentation, the upper band is designated DC-CASPIC. (*, 
p<0.05) 
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LPS, lane 2). The primers were specific to the two flanking ends of the CARD-
like domain. Interestingly, two PCR products with distinctive sizes were observed 
from both the treated and untreated DCs: one is approximately 350 bp while the 
other is approximately 450 bp (Figure 10A). The expected size of DC-CIITA is 
349 bp; therefore, the lower band could likely be the CARD-like domain of DC-
CIITA. The size of the upper band was about 100 bp larger than was expected. 
Thus, it is possible that this band was derived from other genes or other isoforms 
of DC-CIITA. 
Furthermore consistent with previous reports (Landmann et al., 2001), the 
mRNA of DC-CIITA is significantly down-regulated in DCs during the LPS-
mediated maturation (p < 0.05) whereas the upper band appears unaffected by 
LPS treatment (p > 0.05) (Figure 10B).  
3.2.3 Bioinformatics analysis of DC-CASPIC 
The two bands from Figure 10A (lane 1) were excised from the agarose 
gel, cloned, and subjected to sequence analysis. DNA sequencing analysis 
revealed that both fragments encode for the CARD-like domain of DC-CIITA 
(Figure 11A). However, the larger fragment (474 bp) contains an additional insert 
of 142 nucleotides, compared to with to the smaller fragment (349 bp). This 
insertion has created two ORFs, ORF-1 and ORF-2. Both ORFs contain perfect 
Kozák sequence, which are necessary for efficient translation in eukaryotic cells. 
ORF-1 is longer and starts from the +194 bp position and ends at +478 bp, and it 
encodes for the whole CARD-like domain, with an extra stretch of 28 amino acids 
with no homology to any of the CIITA forms, nor to any known proteins in the 
SwissProt, PIR, PRF, PDB, GenBank, and RefSeq databases (data not shown). 
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This polypeptide encoded by ORF-1 is given the name DC-expressed caspase 
inhibitory isoform of CIITA (DC-CASPIC). A mouse genome database search and 
genomic DNA sequence analysis showed that the 142-nucleotide insertion is part 
of intron 1 of DC-CIITA and that DC-CASPIC is a splice-isoform of DC-CIITA 
(Figure 11B). 
ORF-2 starts from +471 bp and can be translated into a nine amino-acid-
long peptide: MEFQELCYI. The NCBI BLAST result showed that it is also a 
novel peptide and the sequence of its first seven amino acids is very similar to one 
portion of mitochondrial 3-methylcrotonyl-CoA carboxylase alpha subunit 
(132MEFAELC138). Due to time constraints, this study focused only on DC-
CASPIC. 
3.2.4 Generation of a specific rabbit polyclonal antibody against DC-CASPIC  
Although DC-CASPIC is not regulated at the mRNA level during DC 
maturation, it would still be interesting to investigate whether the DC-CASPIC 
protein level changes upon maturation by using the specific antibody against DC-
CASPIC.  
To generate the rabbit polyclonal antibody against the unique 28 amino 
acid C-terminus sequence of DC-CASPIC, the synthesised peptide, 
YGGAYDLTGYLGGNLKPGAREGAPNH, was injected into rabbits. The Myc-
tagged DC-CASPIC construct was then transfected into A431 cells to test the 
specificity of the antibody. Proteins in the cell extract were separated by a 12% 
SDS-PAGE and transferred onto a nitrocellulose membrane. The Myc-tagged DC- 
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Figure 11: Bioinformatics analysis of DC-CASPIC  
 (A) DNA sequencing analysis revealed that the larger PCR product contains an insert of 142 nucleotides which create 2 open reading frames 
(ORF-1 and ORF-2). ORF-1, the longer one, encodes DC-CASPIC. The black box indicates the Kozák sequence or motif. (B) Mouse genome 
database search and genomic DNA sequences analysis shows that the insertion (grey box) is part of intron 1 (white boxes). Boxes in black 
signify CIITA exons. 
Splicing 
Transcription 
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CASPIC proteins were subsequently detected by a Western blotting using this 
polyclonal antibody. The antibody detected a 20 kDa band in cells transfected 
with Myc-DC-CASPIC, but not in cells transfected with a control pDMyc vector 
(Figure 12A, upper panel, lane 1, 3). Moreover, the detection of Myc-DC-
CASPIC could be blocked by its immunogen, a synthetic peptide composed of the 
unique 28 amino acids found at the C-terminus of DC-CASPIC (Figure 12A, 
upper panel, lane 4). In DC2.4 cells, a 20 kDa band was also detected by the 
antibody after LPS induction, and the detection was blocked by the immunogen 
(Figure 12B, upper panel, lane 2 and 4). Taken together, the antibody showed 
high specificity towards both exogenous and endogenous DC-CASPIC.  
To avoid the cross-reactivity with CIITA or other proteins of mouse, 
BLAST was carried out with antigenic peptide 
“YGGAYDLTGYLGGNLKPGAREGAPNH” (Expect threshold: 10). The result 
of BLAST showed that there are not sequences producing significant alignments 
with this 28-amino acid peptide in mouse. In addition, the BLAST result by using 
the nucleotide sequence encoding 28-amino acid peptide also showed only one 
unique alignment on mouse chrosome 16 genomic contig. Therefore, the 
algorithm analysis indicated that the possibility for this antibody to recognize 
other peptides was very low. 
Moreover, Figure 12B also showed that the DC-CASPIC protein was 
indeed expressed in DCs and its level was up-regulated during LPS-induced 
maturation.  




Figure 12: Verification of specificity of rabbit polyclonal antibody against 
DC-CASPIC 
(A) The cell extracts from A431 cells, which were transfected with an empty 
pDmyc vector (myc) or Myc-tagged DC-CASPIC (CARD) were probed with the 
DC-CASPIC antibody with or without blocking of immunogenic peptide, or β-
actin antibody. (B) DC 2.4 cells were treated with or without 1 µg/mL LPS for 48 
hours and the cell extracts were probed with the same set of antibodies. 
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3.2.5 Expression profiles of DC-CASPIC 
Next, we sought to analyse the expression profiles of DC-CASPIC in 
various APC cell lines and mouse tissues. An APC cell line survey showed that 
the DC-CASPIC protein was expressed in mouse DCs, dendritic cell lines DC2.4 
and JAWSII and microglia N9 cell-lines, and that their expression levels are 
similar (Figure 13A). The tissue distribution of DC-CASPIC was also examined. 
Homogenates from ten different mouse tissues were tested for the presence of DC-
CASPIC. Out of the ten mouse tissues tested, DC-CASPIC was detectable in six 
tissues, namely those of the brain, liver, kidney, small intestine and colon (Figure 
13B).  
3.2.6 Subcellular localisation of DC-CASPIC 
DC-CASPIC in DCs has been shown to endogenously express in DCs. 
Next, we attempted to visualise the intracellular localisation of DC-CASPIC in 
DCs. Unfortunately, the DC-CASPIC antibody was not able to detect endogenous 
DC-CASPIC by immunofluorescence microscopy. This could likely due to the 
inaccessibility of the DC-CASPIC antibody to the masked epitope at the C-
terminus of the naturally folded endogenous DC-CASPIC protein. Therefore, 
instead of detecting the endogenous DC-CASPIC in DCs, we over-expressed the 
Myc-tagged DC-CASPIC and detected its localisation with an antibody against 
Myc. 
Myc-DC-CASPIC was transfected into A431 cells and the Myc-DC-
CASPIC was detected with an anti-myc antibody using a confocal 
immunofluorescence microscope. The results showed that myc-DC-CASPIC  




Figure 13: Expression profiles of DC-CASPIC 
(A) Immature DCs (DCs), dendritic cells line DC2.4 and JAWSII, microglia cell 
lines N9, were treated with 1 µg/mL LPS and the cell extracts were probed with 
DC-CASPIC and β-actin antibodies. (B) Homogenates from ten different organs 
of a mouse (as indicated) and A431 cells were probed with DC-CASPIC and 
GADPH antibodies. SM, small intestine. 
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 staining pattern displayed a typical mitochondrial-like localisation (Figure 14A). 
Therefore, the cells were then double labelled with anti-myc and cytochrome c 
antibody. This was then followed by staining with FITC- and cy3-conjugated 
secondary antibodies. The confocal immunofluorescence microscopy analysis 
showed that Myc-DC-CASPIC co-localised well with cytochrome c in the 
mitochondria (Figure 14A−C). 
To further confirm the mitochondrial localisation of DC-CASPIC, 
mitochondria were isolated from DC2.4 cells according to the protocol described 
in Materials and Methods (See section 3.1.17). Then, proteins from either total 
cell extract (Total) or from mitochondria (Mit) were separated by SDS-PAGE 
followed by a Western blot analysis with specific antibodies against Myc, TFIIB, 
cytochrome c, DC-CASPIC and. As shown in Figure 14D, DC-CASPIC was 
enriched in the mitochondrial fraction. The Myc and TFIIB proteins served as 
cytosol and nucleus markers, respectively. They were detected in the total cell 
extract but not in the mitochondrial fraction, showing that the mitochondrial 
fraction was relatively pure.  
The localisation of DC-CASPIC in the mitochondria was further verified 
by immunogold electron microscopy. Ultrathin sections of DC2.4 cells were fixed 
and stained with antibodies against DC-CASPIC and cytochrome c followed by 
10nm and 5nm immunogold-conjugated secondary antibodies, respectively. Thus, 
DC-CASPIC and cytochrome c were labelled with 10 nm and 5 nm immunogold, 
respectively. Under the electron microscope, DC-CASPIC, as expected, co-
localised with cytochrome c (Figure 14E) in the mitochondria. Negative staining  








Figure 14: DC-CASPIC co-localises with cytochrome c in mitochondria 
(A−C) A431 cells expressing Myc-DC-CASPIC were fixed and stained with 
antibodies against c-myc and cytochrome c (Cyt c), followed by FITC- and cy3-
conjugated secondary antibodies, respectively. DC-CASPIC and cytochrome c 
were subsequently detected under a confocal microscope. (Scale bar: 10 μm) (D) 
Protein extract from DCs whole cells (Total) or mitochondria (Mit) was separated 
by SDS-PAGE and probed with myc, TFIIB, cytochrome c and DC-CASPIC 
antibodies in a Western blot. Bars represent the density of myc bands (normalised 
to β-actin bands). (E) Ultrthin sections of DC2.4 cells were fixed and stained with 
antibodies against cytochrome c and DC-CASPIC followed by 5nm and 10nm 
immunogold-conjugated secondary antibodies, respectively. DC-CASPIC (Arrow) 
and cytochrome c (Star) were subsequently detected by electron microscopy (Mit: 
mitochondria, N: nuclear, Scale bar: 100 nm).  
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in the nucleus served as a negative control. Thus, the results demonstrate that DC-
CASPIC is enriched in the mitochondria. 
The N-terminus of DC-CASPIC was previously identified to have a weak 
homology to CARD, which is characterised by six α-helices (Nickerson et al., 
2001). To examine whether an intact CARD-like domain is required for its 
mitochondrial localisation, three truncated DC-CASPIC constructs, which were 
made up of amino acid residues 1 to 34, residues 1 to 69 and residues 1 to 95, 
respectively, were generated. They were subsequently termed DC-CASPIC (1−34), 
DC-CASPIC (1−69) and DC-CASPIC (1−95) (Figure 15A). The three truncated 
constructs were cloned into a pDMyc mammalian expression vector. The 
recombinant protein expressed would thus be C-terminus Myc-tagged DC-
CASPIC. 
These constructs were respectively transfected into A431 cells and the 
cells were fixed and doubly labelled with anti-myc and anti-cytochrome c 
antibodies, followed by FITC- and cy3-conjugated secondary antibodies. Under 
the observations of immunofluorescence confocal microscopy (Figure 15B-G), 
Myc-DC-CASPIC (Figure 14C) and Myc-DC-CASPIC (1−95) (Figure 15B, E) 
perfectly co-localised with cytochrome c in the mitochondria. However, Myc-DC-
CASPIC (1−69) co-localised with cytochrome c in the mitochondria, but also 
exhibited some extra-mitochondrial staining (Figure 15C, F). Interestingly, Myc-
DC-CASPIC (1−34) mainly exhibited a cytoplasmic staining (Figure 15D, G). In 
comparison with DC-CASPIC (1−34) and DC-CASPIC (1−69) constructs, DC-
CASPIC (1−34) has α-helices H3 and H4 deleted. This deletion of H3 and H4 













Figure 15: Localisation of different DC-CASPIC truncated constructs inA431 cells and DC2.4 cells 
(A) Generation of DC-CAPSIC truncated constructs. H1a-H6 represents the six α-helices typical of the CARD domain. The final lengths of the 
constructs are as follows: DC-CASPIC (1−34) (1−34 residues), DC-CASPIC (1−69) (1−69 residues) and DC-CASPIC (1−95) (1−95 residues). 
(B−D) Different DC-CASPIC truncated constructs were transfected into A431(B-D) cells or DC2.4 (E-G). The cells were fixed and doubly 
labelled with antibodies against c-myc and cytochrome c (Cyto c), followed by FITC and cy3-conjugated secondary antibodies. The nucleus was 
stained by DAPI (blue). DC-CASPIC and cytochrome c were subsequently detected by confocal microscopy (Scale bar: 10 μm) 
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helices has fully abolished the localisation of DC-CASPIC in the mitochondria. 
Therefore, these two helices are essential for the mitochondrial localisation of DC-
CASPIC.  
3.2.7 Over-expression of DC-CASPIC enhances NO production in DCs  
In view of our observation that DC-CASPIC protein expression was up-
regulated in the mature DCs (Figure 12B), it is interesting to determine the 
possible roles of DC-CASPIC during DC maturation. The pDMyc vector and DC-
CASPIC were transfected into DC2.4 and the effect of DC-CASPIC over-
expression on NO synthesis (one of the key molecules produced by DCs going 
through maturation) was examined in the absence and presence of LPS. The 
culture medium from these cells was subjected to a Griess assay. The results 
showed that NO2- levels were higher in DC-CASPIC over-expressing cells for 
mature stages of DCs (Figure 16, p < 0.01). Thus, it can be concluded that DC-
CASPIC boosts NO production during maturation of DCs. 
To ascertain if the localisation of DC-CASPIC to the mitochondria 
correlates with the induction of NO synthesis, DC2.4 cells stably expressing the 
truncated constructs DC-CASPIC (1−34), DC-CASPIC (1−69), DC-CASPIC 
(1−95) or full-length DC-CASPIC (Figure 15A) were treated with LPS to induce 
DC maturation, then cell culture medium were then collected and assayed for NO 
production by measuring nitrite concentration (a breakdown product of NO). As 
shown in Figure 17A, NO produced in DC 2.4 cells which were transfected with 
full-length DC-CASPIC, DC-CASPIC (1−69) and DC-CASPIC (1−95) was 
approximately 3.1, 3.4 and 2.7 times higher than that of pDMyc-transfected 
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control cells, respectively. This result thus revealed that the deletion of the non-
CARD segments on DC-CASPIC and the last two helices on the C-terminus of 
CARD domain deletion of H5 and H6 helices on the C-terminal CARD domain 
(refer to the schematic diagrams on full-length and truncated DC-CASPIC in 
Figure 15A did not affect the normal function of DC-CASPIC in enhancing NO 
production. Although DC-CASPIC (1−69) increased NO production more 
potently than the full-length DC-CASPIC, it should be noted that DC-CASPIC 
(1−69) was higher in protein expression than the full-length DC-CASPIC (Figure 
17B). This might explain the lower level of NO measured for full-length DC-
CASPIC than for DC-CASPIC (1−69). On the other hand, NO level produced by 
DC2.4 cells expressing DC-CASPIC (1−34) was similar to that of the control. 
Taken together, these results have thus indicated that the H3 and H4 helices are 
necessary for DC-CASPIC to enhance NO production in LPS-induced mature 
DCs.  
3.2.8 Over-expression of DC-CASPIC increases NOS2 protein level 
Since DC-CASPIC up-regulates NO synthesis in DCs, we next examined 
whether DC-CASPIC also induces the expression of NOS2, which is one of major 
forms of NOS in DCs. To address this issue, the pDMyc vector- and DC-
CASPIC-transfected DC2.4 were either uninduced or induced with LPS. Cell 
lysates were separated by SDS-PAGE and analysed by a Western blot using anti-
myc and anti-NOS2 antibodies. NOS2 protein expression was up-regulated in both 
pDMyc- and DC-CASPIC transfected DCs upon LPS induction (Figure 18A, 
compare lanes 1 and 3, and lane 2 and 4). Interestingly, unlike NOS3, NOS2 was  






Figure 16: Over-expression of DC-CASPIC enhances NO production in DCs 
DC2.4 cells were stably transfected either with a pDMyc empty vector (white bars) 
or DC-CASPIC (black bars), followed by no induction or induction with 1 μg/mL 
LPS for 48 hours. The NO production was measured by a Griess assay. (*, p > 
0.05; **, p < 0.01) 
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Figure 17: H3 and H4 helices are essential for DC-CASPIC to enhance NO production 
(A) DC2.4 cells were stably transfected either with a pDMyc empty vector, Myc-DC-CASPIC (1−34), Myc-DC-CASPIC (1−69), Myc-DC-
CASPIC (1−95) or Myc-DC-CASPIC, followed by no induction (white bar) or induction with 1 μg/mL LPS (black bar) for 48 hours. The NO 
production was measured by a Griess assay. Data shown here is the mean ± s.d. from three independent cultures. (**, p < 0.01; *, p > 0.05) (B) 
Cell lysates of DC2.4 expressing different constructs were subjected to a Western blot analysis using anti-myc monoclonal antibodies. β-actin 
was used as loading control. 
CHAPTER 3 DC-CASPIC REGULATES NO SYNTHESIS 
 71
up-regulated in DC2.4 over-expressing DC-CASPIC. Nevertheless, it was 
noteworthy that the DC-CASPIC-construct transfected cells consistently exhibited 
a higher NOS2 protein level compared to the pDMyc vector transfected cells, both 
in the immature and mature DCs. These results indicate that DC-CASPIC over-
expression up-regulates the NOS2 protein level. 
To determine whether the regulation of NOS2 expression by DC-CASPIC 
is at the transcriptional or translational level, NOS2 mRNA level was examined by 
an RT-PCR analysis. As shown in Figure 18B, the over-expression of DC-
CASPIC did not significantly elevate the NOS2 mRNA level at either the 
immature or mature stages of DCs (compare lane 1 and 2 for immature DCs, lane 
3 and 4 for mature DCs). Thus, the regulation of the NOS2 protein expression by 
DC-CASPIC is at a translational level, but not at a transcriptional level. 
3.2.9 NOS2 is a substrate for caspases and DC-CASPIC inhibits caspase 
activity 
In view of our observation that the DC-CASPIC-induced up-regulation of 
NOS2 protein expression was not regulated at the mRNA level, it is logical to 
speculate that NOS2 could be a substrate for proteases in the cytoplasm. An 
analysis of the amino acid sequence of NOS2 revealed at least two conserved 
potential caspase recognition/cleavage sites: 847DETD850 for caspase 3 and 
14YQSD17 for caspase 1 (Luschen et al., 1998). The 14YQSD17 sequence is known 
to be essential for NOS2-NOS2 homodimers formation. Such a homodimer 
formation mediates NO synthesis by NOS2 (Ratovitski et al., 1999). Thus, if a 
14YQSD17 sequence is cleaved by caspases, one would expect the NOS2-NOS2 
homodimer formation and its activities to be disrupted. In contrast, the 847DETD850  
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Figure 18: Over-expression of DC-CASPIC increases NOS2 expression at 
translational level but at not transcriptional level 
(A) The pDMyc vector and Myc-DC-CASPIC construct were transfected into 
DC2.4 cells followed by induction with or without LPS. The cells were lysed and 
subjected to a Western blot analysis with the use of myc, NOS2 and β-actin 
antibodies. The bars represent the densities of NOS2 bands in the Western blot 
analysis (normalises to the β-actin bands). (B) The mRNA was isolated from the 
same set of cells and performed an RT-PCR analysis for the mRNA level of 
NOS2 and β-actin. 
CHAPTER 3 DC-CASPIC REGULATES NO SYNTHESIS 
 73
cleavage site has not been extensively studied. Nevertheless, these findings 
indicate that caspases may be protease candidates involved in the degradation of 
NOS2. To test this hypothesis, DCs were treated with either IFN-γ or a caspase 
inhibitor (CI) and subjected to a Western blot analysis for their NOS2 protein 
level. Treatment with IFN-γ served as a positive control, because IFN-γ is known 
to induce NOS2 gene expression. The Western blot analysis results showed that 
the NOS2 proteins increased upon treatment with the caspase inhibitor (Figure 19). 
This result implies that NOS2 is a substrate for caspases. 
If NOS2 is a substrate for caspases and DC-CASPIC protects it from 
proteolytic degradation, DC-CASPIC may thus inhibit caspase activities. To 
address this possibility, a total cell extract from immature DCs was pre-incubated 
with 1 μg of GST-CARD recombinant fusion protein followed by incubation with 
various caspase substrate peptides. The changes in different caspase activities 
were then analysed according to the protocol described in Materials and Methods 
(See section 3.1.22). Figure 20 shows the relative activities of various caspases 
with their respective controls (total cell extract without pre-incubation with GST-
CARD). It was observed that pre-incubation with GST-CARD significantly 
suppressed the cleavage of p-YVAD (p < 0.01) and p-DEVD peptides (p < 0.01). 
p-YVAD and p-DEVD are substrates of caspase 1 and caspase 3, respectively. 
However, there were no obvious changes in the cleavage of the p-IETD peptide, 
which is a substrate of caspase 8 (p > 0.05) (Figure 20). Therefore, DC-CASPIC 
could inhibit caspase 1 and caspase 3 activities, but not caspase 8 activities.  
Taken together, our results suggest that DC-CASPIC protects NOS2 from 
protein degradation by inhibiting caspase 1 and caspase 3 activities. 









Figure 19: Caspase inhibitor causes an increase in NOS2 protein in DCs 
DC2.4 cells were untreated (lane 1), treated with 10mg/mL IFN-γ for 48 hours 
(lane 2), or treated with 200 nM caspase inhibitor (CI) for four hours (lane 3). The 
cells were then lysed and subjected to a Western blot analysis, using NOS2 and β-
actin antibodies. 






Figure 20: DC-CASPIC inhibits caspase activity in vitro 
Cell extract (300 μg) from DCs was incubated with 1μg of GST or a GST-DC-
CASPIC protein, together with caspase 1 substrate (p-YVAD), caspase 3 substrate 
(p-DEVD), or caspase 8 substrate (p-IETD), respectively, for four hours, then the 
caspase activities were measured. Caspase activity in the control, which was 
incubated with GST protein, was set as 100% percent. (**, p < 0.01; *, p > 0.05) 
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3.2.10 DC-CASPIC interacts with caspase 1 and caspase 3 
Since DC-CASPIC inhibits caspase activity in DCs, there is a possibility 
that DC-CASPIC interacts with caspases through its CARD-like domain. For 
many CARD domain-containing proteins, their biological functions are mediated 
by interacting with other CARD-containing proteins through CARD-CARD 
interaction (Hofmann et al., 1997). Thus, we hypothesised that DC-CASPIC 
inhibits caspase activities through CARD-CARD domain interaction as well. 
CARD domain at the N-terminus of DC-CASPIC was cloned into a pGEX-KG 
vector and expressed as a GST-tagged CARD domain (GST-CARD). The GST-
CARD was then used as bait to pull down its potential interacting partners from 
the total DC cell extract. The GST-CARD successfully pulled down the full-
length caspase 1 which contains a CARD domain and the small unit of active 
caspase 3 (p17), which has no CARD domain (Figure 21). However, the pull 
down experiments did not detect any interaction of GST-CARD with either 
caspase 2 or 4. Thus, our results suggest that DC-CASPIC interacts with caspase 1 
and caspase 3, thereby protecting NOS2 from being degraded, by suppressing the 
proteolytic activities of caspases 1 and 3 (Figure 21). 
3.2.11 NOS3 localises to mitochondria  
Our results show that DC-CASPIC localises to the mitochondria and DC-
CASPIC over-expression in DCs protects NOS2 from degradation (presumably by 
caspases) (Figure 14 and 18). In order to protect NOS2 from caspase-dependent 
degradation, it is important for DC-CASPIC and NOS2 to localise in proximity to 
each other. To address this question, DCs were fixed and incubated with 
antibodies against NOS2 and cytochrome c, followed by FITC and cy3-conjugated  






Figure 21: DC-CASPIC interacts with caspase 1 and caspase 3 in vitro 
The CARD domain at the N-terminus of DC-CASPIC was cloned into a pGEX-
KG vector and expressed as GST-tagged CARD domain (GST-CARD). GST 
(lane 1) or GST-CARD (lane 2) was used as bait to pull down potential 
interacting partners from the total DC cell extract, followed by a Western blot 
analysis using caspase 1, 2, 3 and 4 antibodies. 
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secondary antibody respectively. Cellular localisation of NOS2 and cytochrome c 
was subsequently detected by confocal immunoflorescence microscopy. However, 
interestingly, NOS2 only co-localises partially with cytochrome c and a major 
pool of the NOS2 in DC localises to the cytoplasm (Figure 22).  
Unexpectedly, we observed that NOS3 co-localises well with cytochrome 
c in the mirochondria under immunoflorescence microscopy (Figure 23A). To 
extend the confocal immunoflorescence microscopy results with NOS3 to electron 
microscopy, ultrathin sections of DC2.4 cells were stained with antibodies specific 
for NOS3 and cytochrome c, and labelled with 10nm and 5nm immunogold 
conjugated secondary antibodies respectively. Their co-localisation was further 
verified by immunogold electron microscopy. The results indicated that both 
NOS3 (stars) and cytochrome c (arrows) localised in the mitochondria, although 
NOS3 was also found in the cytosol (Figure 23B). 
3.2.12 NOS3 is shown as one of the probable upstream factors regulating DC-
CASPIC protein expression 
Dawn et al. (2002) and Zhao et al. (2007) demonstrated that NOS3 is 
required for the production of NOS2 protein and NO synthesis in postischemic 
myocardium condition. In their study, the expression of NOS2 protein and mRNA 
was significantly reduced in heart tissues of NOS3-knockout mice. The study 
suggests that NOS3 catalyses production of NO which induces NOS2 synthesis 
via a PKC-dependent signalling pathway (Dawn et al., 2002). In conjunction with 
the study and in view of our observation that LPS induces mRNA and protein 
expression of NOS3 and DC-CASPIC, it is therefore interesting to examine if the  
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Figure 22: NOS2 does not co-localise in mitochondria 
Immature DCs were induced with LPS, then fixed with methanol and stained with antibodies against cytochrome c and NOS2 followed by FITC 
and cy3-conjugated secondary antibodies, respectively. The nucleus was stained by DAPI. NOS2 and cytochrome c (Cyto c) were subsequently 
detected by confocal microscopy. (A) Stereo 3D rendering images of cytochrome c (green) and NOS2 (red) subcellular localisation in DCs 
(Scale bar, 10 μm). (B) X-Z/Y-Z projection of collected confocal images showing localisation of NOS2 with cytochrome c. 
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Figure 23: NOS3 localises to mitochondria 
(A) Immature DCs were induced with LPS then fixed and stained with antibodies against NOS3 and cytochrome c followed by FITC and cy3-
conjugated secondary antibodies, respectively. The nucleus was stained by DAPI. NOS3 and cytochrome c (Cyto c) were subsequently detected 
by confocal microscopy. Arrows indicate the co-localisation of NOS3 and cytochrome c. (Scale bar: 10 μm) (B) Ultrathin section of DC2.4 were 
fixed and stained with antibodies against NOS3 and cytochrome c followed by 5nm and 10nm immunogold-conjugated secondary antibodies, 
respectively. NOS3 (*) and cytochrome c (←) were subsequently detected by electron microscopy (M: mitochondria, N: nuclear, *: NOS3; ←: 
cytochrome c ; Scale bar: 100 nm). 
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expression of DC-CASPIC is affected in NOS3-deficient DCs upon LPS induction. 
To test this possibility, DCs from the wild type and NOS3-/- mice were induced 
with or without LPS. The protein extracts were subjected to Western blot analysis. 
As shown in Figure 24A, LPS treatment increased the DC-CASPIC protein level 
in the wild type cells significantly (lane 1 and 2, p < 0.01). Nevertheless, the 
induction of DC-CASPIC upon LPS treatment was diminished in NOS3-knock 
out mice (lane 3 and 4, p > 0.05). Moreover, knockout of NOS3 reduces the 
expression of DC-CASPIC by 43% in mature DCs (lane 2 and 4, p < 0.01), but 
this effect was less pronounced in immature DCs (lane 1 and 3, p> 0.05). Thus, 
NOS3 indeed plays an important role in regulating DC-CASPIC expression during 
maturation of DCs(Figure 24 A−B). 
Next, we examined whether there is a feedback mechanism in the NOS3-
mediated regulation of DC-CASPIC by investigating whether DC-CASPIC 
enhances NOS3 expression during maturation of DCs. Myc-DC-CASPIC was 
over-expressed in DC2.4 cells and induced with LPS. Myc-DC-CASPIC was then 
detected with anti-myc antibody in Western blot analysis. As shown in Figure 24 
C and D, NOS3 was consistently up-regulated in both the control pDMyc vector 
and Myc-DC-CASPIC transfected cells upon LPS induction. However, DC-
CASPIC over-expression does not seem to enhance NOS3 protein expression in 
DCs (Figure 24 C, D).  
Taken together, our results showed that NOS3 might act upstream of DC-
CASPIC, enhancing DC-CASPIC expression during maturation of DCs. In 
addition, there is a possibility that the regulation of DC-CASPIC by NOS3 could 
be at the translational level. 




Figure 24: NOS3 identified as one of the probable upstream factors 
regulating DC-CASPIC protein expression 
(A) Wild type and NOS3-knockout DCs were treated or untreated with LPS. 
Protein extracts were then separated in SDS–PAGE and probed with DC-CASPIC, 
NOS3 and β-actin antibodies in a Western blot. (B) Bars represent the relative 
density of DC-CASPIC bands in the Western blot analysis (normalised to β-actin 
bands). Data shown were the means ± s.d. from three independent cultures. (C) 
Empty pDMyc or Myc-DC-CASPIC constructs were transfected into DC2.4 cells 
and the cells were either treated or left untreated with LPS. Protein extracts were 
subjected to SDS-PAGE and analysed by myc, NOS3 and β-actin antibodies in a 
Western blot. (D) Bars represent the relative density of NOS3 bands in the 
Western blot analysis (normalised to β-actin bands). Data shown were the mean ± 
s.d. from three independent cultures. (**, p < 0.01; *, p > 0.05) 
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3.2.13 Over-expression of DC-CASPIC enhances antigen presentation 
capability of DCs 
DC-CASPIC is up-regulated during LPS-induced maturation of DCs. The 
up-regulation of DC-CASPIC in turn increases NO production through its 
enhanced interaction with caspases, thus preventing the NOS2 from being 
degraded by caspases. In our working model, although DC-CASPIC is up-
regulated during LPS-induced maturation of DCs and issues in the series of events 
as described above, it is unclear whether DC-CASPIC initiates maturation of DCs 
in the absence of LPS.  
To address this issue, immature DCs were first transfected with mRNA 
encoding DC-CASPIC, followed by flow cytometric analysis of several mature 
DCs surface markers such as MHC class II, CD80 and CD86. As shown in Figure 
22, the transfection of DC-CASPIC mRNA into cells increased the cell surface 
expression of MHC class II (G mean value increased from 32.83 to 53.21) as well 
as both the essential co-stimulatory molecules CD80 (from 3.95 to 5.33) and 
CD86 (from 4.32 to 5.66) in the absence of LPS. Thus, DC-CASPIC promotes 
DCs to display maturation phenotypes (Figure 25). 
Besides increasing the cell surface expression of various markers, the 
functional capability to stimulate T cell proliferation is another critical 
characteristic of mature DCs. Next, we further examined whether DC-CASPIC-
induced mature DCs could stimulate T cell proliferation. 
Immature DC2.4 cells were trnsfected with either pDMyc control vector 
(Myc) or Myc-tagged DC-CASPIC (DC-CASPIC), and then incubated with T 
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lymphocytes. At day 3, IL-2 produced and secreted by T cells into the culture 
medium were quantified by ELISA. As shown in Figure 26A, DC-CASPIC 
enhanced DC-dependent T cell proliferation (IL-2 level) in the absence and 
presence of LPS. Thus, like LPS- and NO-donor-treated DC, immature DC-over-
expressing DC-CASPIC enhances the capability of DCs in inducing T cell 
proliferation/activation. Figure 26B showed the expression of DC-CASPIC-Myc 
proteins in DC2.4 transfected cells.  
Thus, not only does DC-CASPIC promote maturation phenotypes in DCs, 
these DCs are also able to functionally stimulate T cell proliferation. Taken 
together, we have shown that DC-CASPIC initiates maturation of DCs.  
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Figure 25: Over-expression of DC-CASPIC enhances DCs surface markers 
Immature DCs were transfected with mRNA encoding DC-CASPIC. DCs were stained with (A) MHC class II-FITC antibody (Isotype: mouse 
IgG2a, Clone: 25-9-17), (B) CD80-FITC antibody (Isotype: mouse IgG1, Clone: L307.4) , or (C) CD86-FITC antibody (Isotype: mouse IgG2a, 
Clone: FUN-1) . Stained DCs were analysed by flow-cytometry. Control staining (gray histograms) was performed with the corresponding 
isotype IgG, Mouse IgG2a for MHC class II, and mouse IgG1 for CD80 and CD86. 






Figure 26: DC-CASPIC enhances DC-dependent T cell proliferation in vitro 
DC 2.4 cells were either transfected with a pDMyc empty vector or with DC-
CASPIC-Myc. These cells were either uninduced or induced with 1μg/mL LPS for 
24 hours and subsequently co-cultured with T cells isolated from BALB/c mice in 
the medium for 72 hours. (A) Quantification of IL-2 in the medium. (B) Cell 
lysates were subjected to a Western blot analysis using anti-Myc and -β-actin 
antibodies. Statically significant differences (P-value): **, p < 0.01. 
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3.3 Discussion  
3.3.1 Possible type of DCs expressing DC-CASPIC in vivo 
The expression of DC-CASPIC is under the control of promoter I of 
CIITA, which is specifically activated in DCs (Muhlethaler-Mottet et al., 1997). 
There are three categories of DCs, TipDCs, cDCs and pDCs. Our results show that 
DC-CASPIC may be specifically expressed in TipDCs, but not in cDCs or pDCs. 
TipDCs are characterised by their detectable levels of TNF-α, NOS2 and 
myristoylated alkaline-rich protein kinase C substrate (MAC), their intermediate 
cell surface expression level of CD11c, a high expression level of CD11b and the 
absence of CD4 or CD8 expression. The development of TipDCs is dependent on 
GM-CSF. In the mice that are genetically deficient in the GM-GSF receptor, 
monocytes which are precursors of DCs, fail to develop into MHC class II 
positive TipDCs generations, even though they had entered the spleen of the 
inflamed recipients (Shortman and Naik, 2007). In vitro, TipDCs can be cultured 
from mouse bone marrow-derived or human monocytes that are stimulated with 
GM-CSF (Randolph et al., 2002; Nikolic et al., 2003). Our results also show that 
DC-CASPIC expresses in this type of cells.  
In addition, the expression of DC-CASPIC in various tissues using a 
Western blotting analysis revealed that it is mainly expressed in the kidney, liver 
and small intestine. Accordingly, TipDCs has been shown to express in kidney, 
liver and intestine of a mouse. In the kidney, although the dichotomy between 
DCs and macrophages was not clear, most of the CX3CR1+ cells were identified 
as DCs. This type of DCs exhibits high expression level of MHC class II, CD11b 
CHAPTER 3 DC-CASPIC REGULATES NO SYNTHESIS 
 88
and CD11c in kidney infection that are similar to TipDCs (Kurts, 2006). In the 
liver, CD11b+CD11c+MHC class IIlo hepatic DCs are found in mouse (Lau and 
Thomson, 2003). In addition, mouse hepatic non-parenchymal cells (NPCs) are 
also able to form mouse bone marrow-derived DCs in the culture medium 
supplemented with GM-CSF (Randolph et al., 1999). These studies may suggest 
the existence of TipDCs in the kidney and liver. In the small intestine, according 
to Randolph’s model, migratory monocyte-derived DCs are induced by the 
inflammatory stimulus and resemble TipDCs, although such kinds of DCs are 
CD8α- and characteristically have a lower CD11c expression (Lu et al., 1994). 
Tissue survey results show that DC-CASPIC is absent in the thymus and 
spleen, which are rich in cDCs (Ardavin, 2003a); therefore DC-CASPIC does not 
seem to be expressed in cDCs. DC-CASPIC is also probably not expressed in 
pDCs, as promoter I which is necessary for the transcription of DC-CAPSIC is 
inactive in pDCs (LeibundGut-Landmann et al., 2004). 
Besides TipDCs, DC-CASPIC has also been found to express in mouse 
brain, and was detected in a N9 microglia cell line and brain extract. 
 3.3.2 DC-CASPIC and NOS 
An association of NOS-like proteins with mitochondria has previously 
been demonstrated immunohistochemically (Kobzik et al., 1995; Bates et al., 
1996). Further supporting evidence is provided by the detection of nitric oxide 
synthase activity in mitochondria (Tatoyan and Giulivi, 1998). Consistent with 
these studies, our Western blot and confocal analysis results using a monoclonal 
NOS3 antibody (immunogen: amino acid residues 1030–1209) also reveal the 
CHAPTER 3 DC-CASPIC REGULATES NO SYNTHESIS 
 89
existence of NOS in mitochondria. In accordance with our results, a study showed 
the docking of NOS3 to the cytoplasmic face of mitochondria as revealed by 
immunogold electron microscopy (Gao et al., 2004). Further their studies are in 
consistent with our observations, which is that most NOS3 proteins co-localised 
with cytochrome c in the mitochondria. The co-localisation of NOS3 and 
cytochrome c may also facilitate the interaction of these two molecules. For 
example, the NOS3 product NO has been reported in previous studies to bind 
directly and reversibly to cytochrome c oxidase. Such binding occurs in 
competition with oxygen, resulting in the inhibition of cytochrome c oxidase 
activity (Cleeter et al., 1994; Clementi et al., 1998).  
 The localisation of NOS3 and DC-CASPIC in mitochondria may also 
provide the possibility of their interactions. Indeed, there is less DC-CASPIC 
protein in NOS3-/- DCs than in the wild type DCs (as seen in two independent 
experiments with p < 0.05). Moreover, the increase of DC-CASPIC is 
accompanied with increase in NOS3 in the DCs, Therefore, these results may 
suggest that the expression of DC-CASPIC in the DCs is at least partially 
regulated by NOS3. 
 NOS3 is also responsible for the synthesis of NO. NO has previously been 
reported involved in the regulation of protease enzymes activities. For instance, 
NO inhibits caspase activity and causes the increase of syntaxins, adaptins, vti1a 
and vti1b protein levels in mature DCs (Wong et al, 2004). In macrophages, the 
exposure of cells to S-nitrosoglutathione and the excess stimulation of endogenous 
NO production could result in the inhibition of ubiquitin-proteosome system-
associated proteins such as parkin (E3 ligase) and Uch-L1 (de-ubiquitinating 
CHAPTER 3 DC-CASPIC REGULATES NO SYNTHESIS 
 90
enzyme that recycles ubiquitin) activity (Glockzin et al., 1999). Therefore, it is 
possible that NOS3 regulates DC-CASPIC expression either by inhibiting caspase 
or by the ubiquitin proteosome system, which is carried by its product, NO. The 
screening of the DC-CASPIC protein sequence did not reveal any potential 
caspase cleavage sites on the DC-CASPIC, but a computer analysis of the DC-
CASPIC protein sequence with the program PESTFIND revealed one potential 
PEST sequence (64KGDLDLTFLSWVCNSLQAPTVE86), which is a 
ubiquitination target (Rogers et al., 1986; Rechsteiner and Rogers, 1996). 
Therefore, the degradation of DC-CASPIC in the mitochondria might be regulated 
by the ubiquitin-proteosome system, which is also found to localise to 
mitochondria in DCs (Liu et al., 2003). Moreover, ubiquitination is also one of the 
post-translational mechanisms of DC-CIITA, which derives from the same 
promoter as DC-CASPIC (Towey and Kelly, 2002; Schnappauf et al., 2003). Thus, 
it is possible that NOS3 protects DC-CASPIC from ubiquitination in DCs. Further 
experiments to prove the existence of ubiquitination on DC-CASPIC may be 
needed to confirm this hypothesis. 
 NOS2 is another major source of NO in mature DCs. Although NOS2 
expression can be regulated primarily at a transcriptional level (Xie et al., 1994; de 
Vera et al., 1996), translational and post-translational regulations are also 
important for NOS2 expression and function. Several proteins such as 
glucocorticoids, caveolin-1 and heat shock protein 90 (hsp90), have been reported 
to interact with NOS2 and cause NOS2 degradation (Kone et al., 2003). These 
post-translational regulations on NOS2 probably occur in or near the mitochondria 
since hsp 90 is reported to localise in mitochondria (Kang et al., 2007), and 
caveolin-1 is also shown to associate with mitochondria (Mellgren,;Li et al., 2001). 
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Our findings showing the existence of DC-CASPIC in mitochondria suggest its 
possible role in regulation of NOS2 activity. Similar to hsp90 and caveolin-1, the 
results in this study reveal that DC-CASPIC may also regulate NOS2 in or in the 
vicinity of the mitochondria.  
 Additionally the results indicate that NOS2 protein expression is indirectly 
regulated by NOS3, which is able to enhance DC-CASPIC expression. This 
hypothesis is supported by previous studies, showing that the expression of NOS2 
is partially dependent on NOS3 in LPS-induced macrophages (Connelly et al., 
2001; Connelly et al., 2005). 
3.3.3 DC-CASPIC and caspase family proteins 
In this study, the incubation of GST-CASPIC with DC2.4 cell lysate 
decreases the activities of caspase 1 and caspase 3 but not caspase 8. The protein 
interaction assay also shows that GST-tagged DC-CASPIC but not GST alone is 
able to pull down caspase 1 and caspase 3 in vitro. One interpretation of these 
results is that the binding of DC-CASPIC to caspases, especially to caspase 1, 
inhibits the activities of the latter. The decrease of caspase activities then partially 
prevents the degradation of NOS2 which contains at least two conserved potential 
caspase recognition/cleavage sites: 847DETD850 for caspase 3 and 14YQSD17 for 
caspase 1 (Luschen et al., 1998). NO in turn acts as a caspase inhibitor to uphold 
the amount of NOS2 protein in the DCs. 
As a CARD domain-containing protein, DC-CASPIC may also interact 
with other CARD-containing proteins. There are at least three categories of 
CARD-containing proteins that are involved in immune responses, namely 
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nucleotide-binding oligomerisation domain proteins (NOD) (NOD1, NOD2, 
CIITA), Retinoic acid-inducible gene-I (RIG-I), Melanoma differentiation gene 5 
(MDA5), Dexh box polypeptide 58 (DHX58) and caspases. 
NOD proteins are mainly involved in the LPS induced-DC maturation 
pathway. For example, NOD1 is a cytoplasmic receptor for LPS. The purified 
NOD1 protein was originally found to associate with a radiolabelled LPS fraction 
from E.coli, and the binding of the NOD1 to LPS is required for the activation of 
NF-κB (Inohara et al., 2001). The mutational analysis demonstrated that the 
CARD domain of NOD1 is necessary and sufficient for the activation of NF-κB, 
implying that the CARD domain of NOD1 protein functions as an effector domain 
(Inohara et al., 1999). Moreover, the interaction of NOD1 with RICK is also 
dependent on the CARD domain, which is critical for the activation of the NF-κB 
pathway (Chin et al., 2002). However, the possibility of DC-CASPIC interacting 
with the NOD protein is low. In DC2.4, DC-CASPIC up-regulated the expression 
of NOS2 at the translational but not at the transcriptional level, as is shown by 
RT-PCR.  
Retinoic acid-inducible gene I (RIG-I) is responsible for the reorganisation 
of intracellular viral dsRNA (Yoneyama et al., 2004). The importance of the RIG-
I pathway in antiviral immunity was confirmed by the generation of RIG-I-
deficient mice (Kato et al., 2005), which revealed that RIG-I, but not the TLR 
system, plays an essential role in the IFN-mediated antiviral response in most cell 
types, including conventional DCs. RIG-I contains two CARD domains at its C-
terminus. The CARD domains of RIG-I interact with the adaptor protein MAVS 
(mitochondrial antiviral signalling) and activate its downstream NF-κB pathways 
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(Hiscott et al., 2006). MAVS gene also encodes a CARD domain (Seth et al., 
2005). A mutational analysis revealed that the CARD domain was essential in 
signalling to IRF-3 and NF-κB. Expression of the CARD region alone was not 
sufficient for the induction of IFN-β in response to a viral infection, and a mutant 
lacking the CARD domain exhibited a dominant negative phenotype for a virus or 
the dsRNA signalling of the host response (McWhirter et al., 2005). Besides 
containing a CARD domain, MAVS shares two other similar characteristics with 
DC-CASPIC. First, MAVS was also found to localise to the mitochondria, and 
was detected in a detergent-resistant mitochondrial fraction upon viral infection. 
Its association with mitochondria is necessary for MAVS signalling activity (Yang 
et al., 2007). Second, MAVS also has a protective role for the cells, because the 
knockdown of MAVS gene expression by siRNA enhances apoptosis in DCs (Seth 
et al., 2005). The co-immunoprecipitation of DC-CASPIC and MAVS may shed 
more light on the involvement of DC-CASPIC in the RIG-I-MAVS pathway and 
in the understanding of the physiological functions of DC-CASPIC. 
An intact CARD domain (α-helices 1 to 6) is necessary for CARD-CARD 
domain interaction (Qin, H., Srinivasula, S. M., 1999). Nevertheless, our data 
show that the deletion of α-helices 5 and 6 on the C-terminal CARD domain does 
not affect the proper localisation in the mitochondria and the function of DC-
CASPIC in enhancing NO production. These results possibly indicate that DC-
CASPIC does not carry out its function through CARD-CARD domain interaction. 
Therefore, the screening of interacting partners of DC-CASPIC should not be 
limited only to the CARD domain-containing proteins. 
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3.3.4 DC-CASPIC and DC-CIITA 
It is also imperative to determine if an over-expression of DC-CIITA will 
result in an increase in the level of NO in the DCs. However, DC-CIITA is likely 
to bind to caspases and its over-expression is also likely to cause an increase in 
NO production. The idea that the major part of the DC-CASPIC protein is present 
only in DC-CIITA but not in type III and type IV CIITA, yet with all three are 
being able to transactivate the same set of genes such as MHC class II, CD74 and 
H2-M, suggests that this CARD domain may be distinct and independent from the 
other functional domains that make up the 3D conformation of type III and type 
IV CIITA. Thus, the CARD domain will still be able to bind to caspases and 
regulate their activities in the native form of DC-CIITA. Despite the extensive 
work done on CIITA to date, the localisation of DC-CIITA has not been 
investigated and it will be interesting to determine if it localises to the 
mitochondria. Localisation studies on CIITA thus far have focused only on the 
type III human CIITA (1130aa) which does not contain the CARD-like domain 
and which it has been reported to be found both in the nucleus and the cytoplasm 
(Cressman et al., 2001). The C-terminal two-thirds, which are shared among all 
CIITA proteins, contain at least two nuclear localisation signals (NL2 and NL3) 
and are implicated in localisation to the nucleus. The presence of these signals in 
the full-length DC-CIITA might thus override those present in the CARD-like 
domain, affecting its localisation to the mitochondria. However, it is interesting to 
note that the GTP-binding domain found in CIITA has been reported to regulate 
its nuclear export (Raval et al., 2003) and that the cellular localisation of CIITA is 
tightly controlled. This has been suggested to act as a regulator for the 
maintenance of steady-state levels of MHC class II in APCs. This also provides a 
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reservoir of CIITA to affect a rapid increase in MHC gene expression in response 
to changes in the external milieu. If CIITA indeed plays multiple functions besides 
being a transactivator, the reason for this tightly controlled cellular localisation of 
CIITA becomes apparent. The interaction of DC-CIITA and caspases (if proven) 
should occur in the cytoplasm and therefore the cellular distribution of CIITA 
should be a dynamic one that is determined by its various translocation signals. 
3.3.5 The functions of DC-CASPIC 
MHC class II and related genes are the most important target genes of 
CIITA. In addition to the genes encoding classic MHC class II molecules, CIITA 
activates the expression of several genes, encoding accessory proteins required for 
an MHC class II-restricted antigen presentation such as CD74 and H2-M (Chin et 
al., 1997; Nickerson et al., 2001; Masternak and Reith, 2002). This clearly 
remains as the primary function of CIITA. However, a series of recent reports 
have suggested that CIITA may also be implicated in other functions within and 
outside the immune system. In one report, the collagen α2 (I) gene has been 
reported to be repressed by CIITA (Xu et al., 2008). Furthermore, in another 
report, the semaphorin receptor plexin-A1 was observed to express abundantly in 
mature DCs, and CIITA plays essential roles in modulating its expression (Wong 
et al., 2003). This observation is particularly interesting as plexin-A1 expression 
was found to enhance the ability of DCs to promote T cell stimulation. Here, we 
show that DC-CASPIC, a novel splice-isoform of the DC-CIITA that mainly 
encodes the entire CARD-like domain of DC-CIITA, can modulate NOS2 protein 
expression, NO synthesis and antigen presentation in DCs. In our model, DC-
CASPIC protein expression is low in immature DCs. However, upon LPS 
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`induction (mature DCs), the protein expression of DC-CASPIC is induced by 
NOS3, and DC-CASPIC interacts with caspases. In addition the interaction of 
DC-CASPIC with caspases inhibits caspase activity and indirectly up-regulates 
the protein expression of NOS2 and possibly other mitochondrial nitric oxide 
synthase, and thus increases intracellular NO synthesis. Through a positive 
feedback system, NO then further inhibits caspases and enhances the production 
of more NOS2 protein in the DCs. The inhibition of caspases by NO and other 
endosomal proteins is essential for regulating the MHC class II-restricted antigen 
presentation pathway in DCs and T cell proliferation (Wong et al., 2004; 
Santambrogio et al., 2005). Thus, this study strongly suggests that DC-CASPIC 
plays important roles in regulating the antigen-presenting capability of DCs during 
maturation (Figure 27). 
3.3.6 Limitations and future direction 
In this part of the study, a novel protein, DC-CASPIC, which is 
specifically expressed in DCs, has been investigated. DC-CASPIC, which is 
specifically expressed in the mitochondria of DCs, is mainly composed of a whole 
CARD-like domain plus an extra stretch of 28 amino acids with no homology to 
any of the CIITA isoforms. During LPS-induced maturation, the DC-CASPIC 
protein is induced by the up-regulation of NOS3. The up-regulated DC-CASPIC 
may be able to slow down the degradation of NOS2 by inhibiting activities of 
caspases, especially caspase 1 and caspase 3, through CARD-CARD domain 
interaction, thus resulting in an increase in the level of NO. The increase of NO 
level then promotes the maturation of DCs, which is observed in DC-CASPIC 
over-expressing cells. However, there are still several limitations in this project. 
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First, both DC-CASPIC and DC-CIITA are transcripted from same 
promoter and share same precursor mRNA. Therefore, it is rather technically 
challenging to further confirm the roles of DC-CASPIC in antigen presentation 
and T cell activation by specifically knockdown DC-CASPIC using siRNA 
transfection without affecting the expression of DC-CIITA. Second, it would be 
much more informative to have DC-CIITA full-length protein as control in all of 
tissue survery, cellular location and protein function studies. However, 
unavailability of DC-CIITA specific antibodies hinders these experiments. Third, 
our results revealed that DC-CASPIC localised in mitochondria by using overe-
expression of myc-tagged DC-CASPIC. And this result is further confirmed by 
cell fractionation experiment which showed that DC-CASPIC was enriched in 
mitochondrial fraction in DCs. Unfortunately, the DC-CASPIC antibody we raised 
is not able to stain the endogenous DC-CASPIC although this antibody 
successfully detects endogenous DC-CASPIC in Western blot. This may due to 
the epitode is enclosed in whole cells but open after cell is lyesed. However, it will 
be great interesting to directly show the mitochondrial localisation in other types 
of DCs such as bonafide DCs. In addition, the mutagenesis study showed that H3 
and H4 helices are necessary for DC-CASPIC mitochondrial localisation and for 
its enhancement on NO production. Nevertheless, the possibility cannot be 
excluded that deletion of helices after helices from an integrated domain can 
generate artificial binding sites or destroy the overall integrity of the domain. It 
might not tell which region is involved in binding. A point mutagenesis study at 
residue level would be much more informative. Fourth, although the initial 
localisation study has led to the discovery of several interacting partners of DC-
CASPIC, such as NOS3, NOS3, caspase 1 and caspase 3, there may still be other 
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potential interacting partners in the cells. A pull-down experiment followed by a 
protein sequence analysis will help to screen out the potential candidates. 
Moreover, even though the pull-down assay and immunoprecipitation show the 
binding of DC-CASPIC to the caspases, the detailed mechanism of this binding is 
still unclear. Future studies on the truncation mutation and crystal structure of DC-
CASPIC may provide insights into this question. 
In conclusion, this study on DC-CASPIC demonstrates that DC-CASPIC 
is one of the key molecules that regulate NO synthesis and antigen presentation 
during maturation of DCs. A novel regulatory pathway has been demonstrated on 
DC-CASPIC in antigen presentation by DCs. Further identification of DC-
CASPIC functions with its role in maturation of DCs would provide a new 
biomarker with potential therapeutic intervention.  







Figure 27: Interactions of DC-CASPIC with NOS2 increase NO production 
and antigen presentation capability of DCs 
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4.1 MATERIALS AND METHODS 
4.1.1 Mice 
C57/BL 6J wild type, NOS3-/- and NOS2-/- mice (I-Ab, I-Eb) were 
purchased from Jackson Laboratory (Bar Harbor, USA). BALB/c wild type mice 
(I-Ad, I-Ed) were purchased from centre for animal resources Singapore. All 
protocols on mice are conducted under the Institutional Animal Care and Use 
Committee (IACUC), National University of Singapore. 
4.1.2  Cell lines and cell culture medium 
Mouse dendritic cell line, DC2.4, was kindly provided by Dr. Kenneth 
Rock (University of Massachusetts Medical Centre, Worcester, USA). Mouse 
dendritic cell line JAWSII and microglia cell line N9, was obtained from the 
American Type Culture Collection (ATCC) (Manassas, USA). Dulbecco’s 
Minimal Eagles medium (DMEM medium), Opti-MEM, Fetal bovine serum (FBS) 
and MEM non-essential amino acids were purchased from Invitrogen (Carlsbad, 
USA). Effectene transfection reagents used for transfection were purchased from 
Invitrogen (Carlsbad, USA). Tissue culture flasks, plates and other disposables 
were either from Nunc (Rochester, USA).  
4.1.3  Antibodies and other reagents 
NG-Monomethyl-L-arginine (L-NMMA), spermine NONOate, 
lipopolysaccharide, E. coli (LPS), caspase inhibitor I, caspase 1 inhibitor, caspase 
I inhibitor VI, caspase-5 inhibitor 1, caspase 3 inhibitor III and Carboxy 
fluoroscein succinimidyl ester (CFSE) were purchased from Calbiochem 
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(Darmstadt, Germany). Granulocyte/Macrophage colony stimulating factors (GM-
CSF) and macrophage colony stimulating factors (M-CSF) were purchased from 
R&D Systems (Minneapolis, USA). Greiess reagent was purchased from Sigma-
Aldrich (St. Louis, USA). The chromatic caspase activity kit was purchased from 
Calbiochem (Darmstadt, Germany). Ficoll-paque plus was purchased from GE 
Healthcare (Bjőrkgatan, Sweden). Other chemical reagents which are not 
mentioned here are all from Sigma-Aldrich (St. Louis, USA). 
Protein A/G coupled sepharose beads were purchesed from Amersham 
Biosciences (Buckinghamshire, UK). Reduced glutathione and glutathione 
agarose beads were purchased from Sigma-Aldrich (St. Louis, USA). 
QIAquick gel extraction kit, Miniprep DNA Purification Kit and Maxi 
DNA Purification Kit were purchased from Qiagen (Hilden, Germany).  
Restriction enzymes, T4 DNA ligase, Taq DNA polymerase, Pfu DNA 
polymerase, T7 or SP6 polymerase, M-MLV reverse transcriptase, and calf 
intestine alkaline phosphatase (CIP) were purchased from Promega (Madison 
USA). A-Plus polymerase was purhcased from Epicentre Biotechnoloies 
(Madison, USA). Caspase 1 and caspase 4 enzymes were purchased from 
Calbiochem (Darmstadt, Germany). 4',6-Diamidine-2'-phenylindole 
dihydrochloride (DAPI) was purchased from Vector Laboratories (Burlingame, 
USA).  
The primary antibodies used in this study are listed in table 4. The various 
goat anti-mouse/anti-rabbit immunoglobulin conjugated to either fluorescein 
isothiocyanate (FITC), cyanine dyes 3 (Cy3) or rhodamine were purchased from 
CHAPTER 4 NOS2 INTERACTS WITH CD74 
 103
Jackson Immunoresearch Laboratories (West Grove, USA). The corresponding 
IgG for isotype control were purchased from BD Biosciences (San Jose, USA). 
The secondary antibodies, i.e. goat anti-mouse / anti-rabbit antibodies (HRP-
conjugated) and nitrocellulose membrane were purchased from Amersham 
Biosciences (Buckinghamshire, UK). West Pico Supersignal substrate/enhancer 
was purchased from Perice Chemical (Rockford, USA). 
Table 4: Antibodies used in CD74 study 
Antibody Isotype Clone name Flourochrome Company 
CD74 Rat IgG2b IN-1 -- BD Biosciences, San Jose, USA 
C-myc Mouse IgG1 9E10 -- EMD Biosciences, Inc. Calbiochem, USA 
NOS2 Mouse IgG1 2 -- BD Biosciences, San Jose, USA 
NOS2 Rabbit IgG Polyclonal -- BD Biosciences, San Jose, USA 
NOS3 Mouse IgG1 3 -- BD Biosciences, San Jose, USA 
I-A/I-E Mouse IgG2b M5/114.15.2 -- BD Biosciences, San Jose, USA 
α-adaptin Mouse IgG1 8 -- BD Biosciences, San Jose, USA 
γ-adaptin Mouse IgG1 8 -- BD Biosciences, San Jose, USA 
Vti1a Mouse IgG1 45 -- BD Biosciences, San Jose, USA 
Vti1b Mouse IgG1 7 -- BD Biosciences, San Jose, USA 
β-actin Mouse IgG1 AC15 -- Sigma-Aldrich, Inc. USA 
c-myc Rabbit IgG Polyclonal -- Santa Cruz Biotechnology Inc., Cruz, USA 
Caspase 1 Rabbit IgG Polyclonal -- Santa Cruz Biotechnology Inc., Cruz, USA 
Caspase 3 Rabbit IgG Polyclonal -- Santa Cruz Biotechnology Inc., Cruz, USA 
Caspase 11 Goat IgG Polyclonal -- BD Biosciences, San Jose, USA 
Syntaxin 8 Mouse IgG2a 48 -- BD Biosciences, San Jose, USA 
CD11c Hamster IgG1 HL3 FITC BD Biosciences, San Jose, USA 
CD80 Mouse IgG1 L307.4 FITC BD Biosciences, San Jose, USA 
CD86 Mouse IgG1 FUN-1 FITC BD Biosciences, San Jose, USA 
I-Ab Mouse IgG2a 25-9-17 FITC BD Biosciences, San Jose, USA 
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4.1.4  Cell culture 
4.1.4.1 Culture of DCs 
C57/BL 6J wild type and NOS2-/- mice (I-Ab, I-Eb) were sacrificed by CO2 and 
sterilised by soaking into 70% ethanol for one minute. After peeling away the fur 
by forceps, the hand legs were cut out and put into plain DMEM and the muscles 
were scraped off by forceps and blades. Before filtering with 70 μM mesh nylon 
screen, the hematopoietic stem cells were flushed out from the resulting long 
bones with 21 G needle and 1 mL syringe into DMEM supplemented with 5% 
FBS containing 20 ng/mL of GM-CSF. Then cell number and viability were 
examined by hemocytometer and trypan blue stain before seeding into cell culture 
dishes. On day 2, 4 and 5, half of volume of old DMEM medium was replaced 
with same volume of fresh complete DMEM medium with 15 ng/mL of GM-CSF. 
The immature DCs were harvest in day 7 by flushing out with blue tips or by 5 
μM EDTA. To induce cell maturation, the day five cells were further subcultured 
in DMEM supplemented with 1 μg/mL LPS (Sigma-Aldrich, St. Louis, USA) for 
40–48 hours. 
4.1.4.2 Culture of primary macrophages 
Bone marrow-derived macrophages were cultured with the same protocol 
as described in section 4.1.4.1. Instead of GM-CSF, complete DMEM is 
supplemented with 20 ng/mL M-CSF. 
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4.1.4.3 Thymocyte isolation 
BALB/c mice were sacrificed by CO2 and sterilised by soaking into 70% 
ethanol for one minute. Freshly removed thymus was placed in 60 × 15 Petri 
dishes containing 3 mL complete DMEM. Using a circular motion, the thymus 
was pressed against the bottom of the Petri dish with the plunger of 5 mL syringe 
until mostly fibrous tissue remained. Clumps in the suspension were further 
dispersed by drawing up and expelling the suspension several times through a 5 
mL syringe equipped with a 19 G needle. Suspension was expelled into a 
centrifuge tube through a 200 μM mesh nylon screen. After washing one time with 
complete DMEM, the cells were resuspended into 16 mL complete DMEM. Six 
milliliter Ficoll paque phase was layered under the cell suspension carefully 
followed by centrifugation for centrifuge 15 minutes at 800 g at room temperature. 
No brake was used in centrifugation. Thymocyte cells floating on top of the high-
density solution were isolated by moving pipette tip over the surface of high-
density layer and by drawing cells up in a 5 mL pipette. Thymocytes were 
transferred into another tube and washed twice with complete DMEM. Then cell 
number and viability were examined by hemocytometer and trypan blue stain 
before seeding into cell culture dishes. Cells were seeded into 24-well plate with a 
cell density of 3 × 106 cells/well and were maintained in the DMEM medium 
supplemented with 50 ng/mL of IL-2. 
4.1.4.4 Culture of cell lines 
DC2.4 and N9 cells were maintained in DMEM supplemented with 10% 
FBS, antibiotics and L-Glutamine (Invitrogen, Carlsbad, USA). JAWS II cells 
were maintained in DMEM supplemented with 10% FBS and 2ng/mL IL-2. The 
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mammalian expression vectors used were either pCDA3.1 or pDMyc (modified 
pCINeo vector with two copies of Myc tag at the 5’ end). Cells were plated into 
plates or dishes and grown for 24 hours to a confluency of 50−60%. 
Lipofectamine 2000 (Invitrogen, Carlsbad, USA) and Effectene (Invitrogen, 
Carlsbad, USA) were used as transfection reagents for DC2.4 cells according to 
the manufacturers’ instructions. Cells were harvested for microscopic examination 
20 hours after transfection.  
4.1.5 Mix lymphocyte reaction assay 
Twenty thousand DCs were co-cultured with 2 × 106 CFSE-labelled T 
cells. For CFSE labelling, purified thymocytes were resuspended with 0.1% (w/v) 
BSA in PBS at a density of 5 × 106 cells/mL and were labelled for ten minutes at 
37 °C with 0.3 µM CFSE. CFSE-labelled cells were 'quenched' with PBS 
containing 5% (v/v) FBS and were washed twice with PBS containing 5% (w/v) 
BSA. T cell division was assessed by FACS analysis after 48 or 72 hours of co-
culture. 
4.1.6 Molecular cloning 
The DNA fragment to be cloned into a specific vector was either amplified 
by polymerase chain reaction (PCR) or restriction digested from another plasmid 
DNA. The sequences of the primers used for PCR normally included the sequence 
recognised by specific restriction enzymes selected for the cloning. Ten 
microgram of vectors were typically digested overnight at 37 °C by one unit of 
restriction enzymes and dephosphorylated by one unit of calf intestinal 
phosphatase for 45 minutes at 37 °C. One unit of ligation was performed using T4 
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DNA ligase, with the ligation mixture incubated overnight at 4 °C. 
Transformation was then carried out by incubating the ligation mixture with E. 
coli DH5α competent cells on ice for 30 minutes. Cells were then heat-shocked for 
one minute in a 42 °C water bath. Lysogeny broth (LB) was then added to the 
cells and the cells were incubated for 45 minutes at 37 °C for recovery. The cells 
were then plated out onto LB plates supplemented with 100 mg/mL ampicillin and 
incubated at 37 oC overnight. Recombinant clones were verified by automated 
sequencing. 
4.1.7 Reverse transcription 
Total RNA was extracted from cells using Trizol reagent (Invitrogen, 
USA) according to manufacturer’s instructions. Total RNA was then recovered by 
precipitation with isopropyl alcohol. Synthesis of cDNA from mRNA transcripts 
was performed using the following: 3 μg RNA, 1.5 μg oligo (dT) in a reaction 
volume of 25 μL. Samples were heated at 70°C for 5 minutes, placed on ice 
immediately and then treated with 0.5 μL RNase inhibitor, 5 μL MLV-RT buffer, 
10 mM dNTP, followed by incubation at 42 °C for two minutes. After a pulse 
spin, 2 unit of MLV reverse transcriptase was then added to the samples and were 
incubated at 42 °C for 90 minutes. After the incubation, samples were heated to 70 
°C for five minutes and then stored at -20 °C.  
4.1.8 PCR-based site-directed mutagenesis 
Wild type CD74 recombinant plasmids were used as templates for 
mutagenesis. Template-specific mutagenic primers were designed for the PCR-
based deletion mutagenesis, as shown in Table 5. Briefly, a 50 μL reaction system 
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containing 5–50 ng wild-type plasmid, 0.25 μM of sense and antisense mutagenic 
primers respectively, 0.2 μM dNTPs and 2.5 unit of Pfu DNA polymerase was 
subjected to 16 thermal cycles (95 °C for one minute, 55 °C for one minute, and 
72 °C for six minutes; final extension at 72 °C for 20 minutes). Fifteen microliter 
of the PCR products were then digested with one unit of corresponding restriction 
enzymes and ligated unto respective vectors followed by transformation into 
E.coli DH5α competent cells by heat shock. The mutant sequences were then 
verified by automated DNA sequencing. 
Table 5: Primers used in CD74 study 





Sense      
5’GGAATTCCATGGATGACCAACGCGACCTCATCTCTAACCAT3’ 
Antisense   




Sense     
5’GGAATTCCATGGATGACCAACGCGCCCTCATCTCTAACCAT3’ 
Antisense   
5’ CTCTAGAGCTCACAGGTGACTTGACCCAG 3’ 
 
4.1.9 In vitro transcription of capped mRNA  
The constructs were linearised by digestion with an appropriate restriction 
endonuclease followed by purification with QIAquick gel extraction kit (Qiagen). 
The in vitro transcription was performed with T7 polymerase according to the 
manufacturer’s instruction (Promega, Madison USA). Briefly, a 50 μL reaction 
system containing 5 μg linear DNA templates, 25 μM of rNTPs, 0.2 μM dNTPs, 4 
μM m7G Cap analog and 5 U of T7 polymerase was incubated at 37 oC for three 
hours. After that, 8 U of A-plus poly (A) polymerase and 1mM ATP were added 
to the mixture and further incubated for 30 minutes to generate a poly (A) tail. 
After performing the in vitro transcription reaction, the mRNA was purified by 
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phenol extraction followed by ethanol precipitation. The RNA concentration was 
determined by absorbance at 260 nm and visualised by denaturing gel 
electrophoresis. 
4.1.10 mRNA electroporation 
DCs were harvested at day six with 2 mM EDTA, washed twice with 
serum-free Opti-MEM and resuspended to a final concentration of 4×107 cells/mL 
in Opti-MEM medium. Subsequently, 100 µL cell suspension was mixed with 
20µg mRNA and electroporated in a 0.2 cm-cuvette (voltage: 300 V, capacitance: 
150 µF resistance: 100 Ω) using the GenePulser II apparatus (Bio-Rad). After 
electroporation, the cells were transferred to fresh culture medium containing GM-
CSF or induced with 1 µg/mL LPS. The cells were cultured for 24 hours to allow 
full maturation. 
4.1.11  Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
SDS-PAGE gels were cast with the Bio-Rad miniprotein III gel casting 
system. The resolving gel contained different percentages of 
acrylamide/bisacylamide mixture (30% with a ratio of 29:1) in 0.375 M Tris-Cl, 
pH 8.8 and 0.1% (w/v) SDS. The stacking gel contained 4% (v/v) 
acrylamide/bisacylamide in 0.125 M Tris-Cl, pH 6.8 and 0.1% (w/v) SDS. 
Polymerisation was induced by the addition of ammonium persulfate (APS) and 
N,N,N,N,-Tetramethyl-Ethylenediamine (TEMED). Protein samples were 
dissolved in SDS sample buffer (50 mM Tris-Cl, pH 6.8, 2% (w/v) SDS, 100 mM 
dithiothreitol (DTT), 10% (v/v) glycerol and 0.1% (v/v) bromophenol blue) and 
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loaded onto the gel. Gel electrophoresis was typically carried out in Tris-glycine 
buffer (0.3% (w/v) Tris-base, 1.4% w/v Glycine and 0.1% (w/v) SDS) at a 
constant voltage of 100 V. 
4.1.12  Western blot analysis 
The proteins to be identified were subjected to SDS-PAGE separation and 
the separated proteins were then transferred onto nitrocellulose membrane. The 
transfer was carried out in transfer buffer (0.3% (w/v) Tris-base and 1.4% (w/v) 
glycine) with a Bio-Rad wet transfer apparatus (Bio-Rad Kaboratories, Miami 
USA) at constant voltage of 100 V for one hour. The membrane was then blocked 
in 5% (w/v) skim milk followed by incubations with specific primary antibodies 
and appropriate secondary antibodies conjugated to horse radish peroxidase (HRP) 
diluted in 5% (w/v) skim milk. Membranes were washed three times with PBS + 
0.05% (v/v) Tween 20 after each antibody incubation steps. Immunoreactive 
signals were visualised using a chemiluminescent substrate (West Pico supersignal 
Kit, Pierce, Rockford USA) and X-ray films, which were developed using a 
Kodak X-ray film processor (Rochester, USA). 
4.1.13 Immunoprecipitation 
Proteins were extracted from cells and incubated on ice for one hour in 
cold lysis buffer (20 mM Tris [pH 8.0], 10 mM EDTA, 100 mM NaCl, 1 mM 
DTT, 1% (v/v) Brij 98, a polyoxyethylene ether followed by centrifugation at 
13,000 rpm for 15 minutes at 4 oC. Protein exacts (1 mg) were incubated 
overnight with 5 μg of the corresponding antibodies bound to protein G Sepharose 
beads (Pharmacia) in lysis buffer plus 1% (w/v) BSA and 10% (v/v) FBS at 4 oC. 
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Beads were then washed three times in Buffer A (20 mM HEPES, [pH 7.2], 100 
mM KCl, 1 mM DTT, 10 mM EDTA, 0.2 mM ATP, 0.5% (v/v) Brij98) and three 
times in Buffer B (identical to Buffer A except without Brij98) before being 
resuspended in SDS sample buffer. Immunoprecipitated proteins and 5% of total 
the supernatant were separated on SDS-PAGE and analysed by Western blot. 
4.1.14 Paraformaldehyde fixation and immunofluorescence staining 
Cells grown on cover glasses were fixed in 4% (w/v) paraformaldehyde for 
30 minutes at room temperature. The cover glasses in the 6-well or 24-well plates 
were then washed (with rocking for 2−3 minutes) once with PBS, twice with PBS 
supplemented with 100 mM NH4Cl and once with PBS again. The cells were then 
permeabilised with 0.1% (w/v) saponin (Sigma, St. Louis, USA) for ten minutes at 
room temperature. The coverglasses were then incubated with primary antibody 
followed by secondary antibody (conjugated to fluorophore FITC or Texas-Red) 
diluted in staining buffer (5% (w/v) BSA, 2 mM EDTA, 10% (w/v) goat serum in 
PBS). Non-specific binding was removed by washing (with rocking for 2−3 
minutes) three times with PBS supplemented with 1% (w/v) saponin. The 
coverglasses were finally mounted onto glass slides with one drop of Vectashield 
mounting medium. The edges of the coverglass were sealed with nail polish and 
the slides were then ready for viewing under a fluorescence microscope. The 
confocal images were taken using either Olympus Fluoview 500 microscope with 
Fluoview version 5.0 software (Tokyo, Japan). The conventional fluorescent 
images were taken using Olympus BX-60 digital microscope with ImagePro Plus 
software (Tokyo, Japan). 
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4.1.15  Flow cytometry analysis 
Cells were harvested with PBS supplemented with 2 mM EDTA, then 
washed once with staining buffer (5% (w/v) BSA, 2 mM EDTA, 2 mM NaN3 in 
PBS) followed by incubation for 30 minutes on ice with the FITC-conjugated 
antibody. For intracellular staining, cells were fixed and permeabilised with pre-
chilled methanol for two minutes, then incubated with primary antibody followed 
by PE conjugated anti-rabbit IgG. After washing with staining buffer, cells were 
fixed with 1% (w/v) paraformaldehyde and the immunophenotypic analysis was 
performed on a FASCAN flow cytometry (DAKO, Glostrup, 
Denmark). 
4.1.16 Quantification of NO 
NO was assayed by measuring the concentration of stable end product 
NO2-. NO2- production was determined by Griess reaction. Aliquots of culture 
supernatant (100 μL) were incubated with 100 μL of Griess reagent (Sigma, St. 
Louis, USA)at room temperature for ten minutes. The absorbance at 550 nm was 
then measured in an automated plate reader. NO concentration was determined 
with reference to a NaNO2 standard curve. 
4.1.17 Caspase cleavage assay 
Cell were lysed with reaction buffer (100 mM NaCl, 50 mM HEPES, 10 
mM DTT, 1 mM EDTA, 10% (v/v) glycerol and 0.1% (v/v) CHAPS pH 7.4) for 
five minutes at 4 oC. CD74 protein was immunoprecipitated by protein G beads, 
which were pre-bound with CD74 antibody. After washing twice with reaction 
buffer, the immunoprecipitated proteins were resuspended in 30 µL reaction 
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buffer and 10 units of caspase enzyme was added. After three hours of incubation, 
the mixture was resuspended in SDS sample buffer followed by analysis using 
SDS-PAGE and Western blot. 
4.1.18 Caspase activity assay 
Ten million cells were lysed with 1mL lysis buffer (50 mM HEPES, 5 mM 
DTT, 0.1 mM EDTA, 0.1% (v/v) CHAPS, pH 7.4) for four minutes at 4 oC. 
Twenty microgram of protein was incubated at 37 °C in a buffer containing 25 
mM HEPES (pH 7.5), 10% (w/v) sucrose, 0.1% (v/v) CHAPS and 10 mM DTT, 
with the respective colourimetric substrates [caspase 1 substrate VI (Z-YVAD-
pNA), caspase 2 substrate I (Z-VDVAD-pNA), caspase 3 substrate IV (Ac-
DEVD- pNA), caspase-4 substrate II (Ac-LEVD-pNA)] (all from Calbiochem, 
Darmstadt, Germany), in a 96-well, flat-bottom microtiterplate. The cleavage of 
the substrates was quantified by spectrophotometric detection of free pNA (λ= 400 
nm) after cleavage from the caspase peptide substrates after two hours. 
4.1.19 Statistics 
Two tail-student's t-test was used for statistical analyses.
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4.2 Results  
The studies in Chapter 3 have shown the involvement of DC-CASPIC in 
enhancing antigen presentation by increasing NOS2 activity and inhibiting 
caspase activity in DCs. However, some questions in this regulatory mechanism 
remain open. For example, what is the function of NO during maturation of DCs; 
and how does the increase in NO production enhance antigen presentation? An 
iinvestigation into these questions would help to elucidate the function of DC-
CASPIC and to understand the antigen presentation regulation in DCs. 
4.2.1 Nitric oxide initiation of maturation of DCs 
4.2.1.1 The increase of NO in DCs after LPS induction. 
An increase in NO production is one of the characteristics in maturation of 
DCs. There are at least three isoforms of NOS genes in DCs, namely NOS1, 
NOS2 and NOS3. Both NOS2 and NOS3 have been reported to express in DCs 
(Weis et al., 2002; Serbina et al., 2008). To identify the gene responsible for the 
production of NO in maturation of DCs, DCs derived from either NOS2 or NOS3-
knockout mice were subjected to LPS-induced maturation and the NO production 
was analysed by Griess assay. The results showed that the increase in NO 
production in the NOS2 gene knockout DCs was fully abolished; whereas in the 
NOS3 gene knockout mice, NO production was also significantly subdued (p < 
0.01) (Figure 28A). The NO donor, NONOate, was used as positive control for 
NO production. Therefore, the NOS2 gene was the major gene for the production 
of NO, although NOS3 also contributed to NO production. Western blot and RT-
PCR assays also indicated that NOS2 and NOS3 were induced during maturation  
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Figure 28: NOS2 produces NO during the maturation of DCs 
(A) Immature DCs derived from the wild type, NOS2-/- and NOS3-/- mice were either untreated (group 1) or treated with L-NMMA (group 2), 
LPS (group 3), L-NMMA/LPS (group 4), or NONOate (group 5). NO produced by untreated and treated wild-type (black bar), NOS2-/- (white 
bar) and NOS3-/- (grey bar) DCs was detected in a Griess assay. Data shown are the mean ± s.d. from three independent cultures. (B) Immature 
DCs were either untreated (Ctrl) or treated with LPS, and the change in NOS2, NOS3 and β-actin expression were detected by a Western blot 
analysis (upper panel) and RT-PCR (Lower panel) analysis (*, p <0.01). 
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at both the mRNA and protein levels (Figure 28B). Taken together, our results 
suggest that both NOS2 and NOS3 contribute to NO production in LPS-induced 
DCs. Nevertheless, NOS2 was the major NOS that catalysed NO synthesis. 
4.2.1.2 NO increases surface expression of MHC class II, CD80 and CD86  
During maturation of DCs, NO was produced in large amounts by NOS2, 
which was also up-regulated during maturation of DCs (Figure 28A). Despite the 
fact that NOS2 is the major NOS that catalyses the production of NO during LPS-
induced maturation of DCs, it is still unclear whether NO alone could contribute 
directly to the initiation of maturation of DCs and the induction of T cell 
proliferation in the absence of LPS. To address this issue, immature DCs were 
incubated with the NO donor (NONOate) alone and stained for cell surface MHC 
class II, CD80 and CD86 by flow cytometry. Interestingly, we observed that 
NONOate alone was able to up-regulate cell surface expression of MHC class II as 
well as both the essential co-stimulatory molecules CD80 and CD86 in the 
absence of LPS. Furthermore, an increase in surface expression of MHC class II, 
CD80 and CD86 was also observed in DCs over-expressing NOS2 and NOS3. In 
this experiment, LPS-treated DCs were used as a control (Figure 29). Thus, NO 
was able to increase the surface expression of MHC class II, CD80 and CD86. 
4.2.1.3 NO up-regulates endosomal proteins in DCs 
Since NO can induce higher cell surface expression of MHC class II, 
CD80 and CD86 on surface of DCs, it would be interesting to determine whether 
NO could also regulate expression of protein molecules essential for the stability 
and intracellular trafficking of MHC class II complex in DCs. Previous studies  
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Figure 29: NO production enhances cell surface markers of DCs 
Immature DCs were cultured in a medium only (Control), or a culture medium containing LPS or NONOate, or were transfected with mRNA 
encoding either NOS2 or NOS3. Cells were stained with CD80-FITC (upper panel), CD86-FITC (middle panel) and MHC class II-FITC 
antibodies (lower panel), followed by an analysis with flow cytometry. Control staining (red histograms) was performed with the corresponding 
isotype IgG, Mouse IgG2a for MHC class II, and mouse IgG1 for CD80 and CD86. 
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have shown that proteases such as caspases are involved in the degradation of 
molecules localised to the endosomal membrane trafficking pathway in immature 
DCs. The endogenous caspase inhibitor, DC-CASPIC, has also been shown to 
prevent the degradation of membrane tracking-related protein syntaxin 8 (SYN8) 
(Figure 30A). In this pathway, the inhibition of caspase activity results in the up-
regulation of NOS protein and NO synthesis. Therefore, it is possible that NO 
may involve in the regulation of membrane trafficking-related proteins. To test 
this hypothesis, total cell extracts from untreated DCs or DCs treated with LPS, 
caspase inhibitor (CI), or NO donor NONOate were separated by SDS-PAGE, and 
the expressions of various membrane tracking-related proteins including vti1a, 
vti1b, α-adaptin, γ-adaptin and syntaxin 8, as well as NOS2, were detected by 
corresponding antibodies in a Western blot. Both caspase inhibitor (Figure 30B, 
lane 3) NO (Figure 30B, lane 4), as well as LPS treatment (Figure 30B, lane 2), 
increased the expressions of these proteins compared with untreated DCs. These 
results indicate that NO possibly has a similar effect to LPS in the regulation of 
membrane trafficking during the maturation of DCs. 
4.2.1.4 NO enhances antigen presentation capability of DCs 
Other than MHC class II, both the co-stimulatory molecules CD80 and 
CD86 were also up-regulated upon NONOate treatment. In addition, the 
NONOate-treated cells also displayed a similar pattern as mature DCs in the 
expression levels of many proteins. We thus hypothesised that NONOate alone  
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Figure 30: NO up-regulates endosomal proteins in DCs 
(A) DC2.4 cells were lysates and probed with myc, syntaxin 8 (SYN8), NOS2 and 
β-actin antibodies in a Western blot. (B) Immature DCs were cultured in a 
medium alone (Ctrl), or a culture medium containing NONOate (NONOate) or 
caspase inhibitor (CI). Protein extracts derived from various treatments were 
separated by SDS-PAGE and transferred to nitrocellulose membrane. NOS2, α-
adaptin, γ-adaptin, syntaxin 8, vti1a, vti1b and β-actin were detected using 
corresponding antibodies. 
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would be able to enhance antigen presentation in DCs in the absence of a general 
maturation signal such as LPS. To test this hypothesis, immature DCs were either 
untreated or treated with NONOate or LPS (as a positive control) prior to 
incubation with thymocytes in a mixed lymphocyte reaction assay for the 
detection of DC-induced T cell proliferation. Interestingly, DCs treated with 
NONOate alone were able to enhance T cell proliferation, although the 
enhancement was slightly weaker than that observed in LPS-treated DCs (Figure 
31).  
4.2.2 Nitric oxide inhibition of CD74 degradation 
4.2.2.1 NO regulates degradation of CD74 in DCs 
Owing to the fact that NO can induce a higher cell surface expression of 
MHC class II in DCs, it would be interesting to determine whether NO could also 
regulate the expression of protein molecules essential for the stability and 
intracellular trafficking of MHC class II complex in DCs. Day five immature DCs 
were either untreated (control) or treated with NONOate for 12 hours at 37 °C. 
Protein extracts were then separated by SDS-PAGE and probed with antibody 
against CD74 which is essential for MHC class II trafficking and antigen 
presentation in APCs (Matza et al., 2003). NONOate significantly increased the 
expression of CD74 at the protein level in a dose-dependent manner (Figure 32C), 
but not at the mRNA level as shown by reverse transcription-PCR (Figure 32B 
lane 6). LPS, which induced NOS2 expression at both the transcriptional and 
translational levels, also increased CD74 protein expression (Figure 32A lane 3 
and B lane 3).  
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Figure 31: NO enhances the antigen presentation capability of DCs 
CFSE-labelled T cells from BALB/c mice were co-cultured with DCs in a 
medium alone (control), or in a culture medium containing LPS or NONOate. T 
cell proliferation was determined by flow cytometry. The control labelled T cell 
(Negative) was performed similarly but in the absence of DCs 
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To further demonstrate the importance of NO in regulating the expression 
of CD74, immature DCs were either treated with L-NMMA (inhibitor of NOS1, 
NOS2 and NOS3 activities) alone, or treated with both L-NMMA and LPS. L-
NMMA treatment alone did not vary the level of CD74 protein expression in 
immature DCs (Figure 32A lane 2). However, LPS-induced CD74 expression was 
repressed by L-NMMA even in the presence of NOS2 (Figure 32A compare lane 4 
and 3). Interestingly, we also observed that the expression of NOS2 was 
significantly increased in the presence of both LPS and L-NMMA (LPS / L-
NMMA) as compared with LPS treatment, alone (Figure 32A lane 3 and 4). 
Unexpectedly, no increase in NOS2 at the transcriptional level was observed upon 
LPS/L-NMMA treatment as compared with LPS treatment alone (Figure 32B lane 
3 and 4). Instead, a decrease in NOS2 mRNA synthesis was observed. This 
indicated the presence of positive feedback machinery where the inhibition of 
NOS activity by L-NMMA treatment enhanced the stability of NOS2 protein. 
Based on our observations that both LPS and NONOate treatments up-
regulate CD74 expression in DCs, we hypothesised that CD74 could be a substrate 
for caspases in immature DCs. Immature DCs were either untreated (control) or 
treated with 200 µM caspase inhibitor I (CI) for four hours at 37 °C. Protein 
extracts from either untreated or treated DCs were separated by SDS-PAGE and 
probed with antibody against CD74 in Western blot. Interestingly, both p31 and 
p41 isoforms of CD74 were significantly up-regulated in CI-treated DCs (Figure 
32A, lane 1 and 5). This up-regulation of CD74 protein expression in CI-treated 
DCs was not due to the increase in the CD74 mRNA level (Figure 32B, lane 5). 
Furthermore, both LPS and CI treatment did not show significant changes to 
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CD74 expression in the mouse bone marrow-derived primary macrophages, 
suggesting that the effects of LPS and CI on the expression of CD74 are DC-
specific (Figure 32A, lanes 7–9). 
The other question to be answered was the specificity of NO. The results 
showed that NONOate exerts an effect on CD74 degradation at a concentration of 
as low as 1 µM. The effect becomes weak when the concentration is increased to 
50 µM. This might be due to the toxicity of NONOate (Figure 32C). 
4.2.2.2 NO has similar effects as caspase inhibitor in regulating the 
degradation of CD74 protein in DCs 
Since NO has similar effects as the caspase inhibitor in preventing the 
degradation of CD74, we next attempted to investigate whether NO directly 
inhibits caspase activity. The cells extracts from LPS-induced mature DCs or from 
immature DCs induced with NONOate were incubated with different caspase 
substrates (as indicated in Figure 33) for four hours. Our results showed that 
NONOate treatment inhibited around 50% of caspase activity towards most of the 
caspase substrates tested, except for IETD whose cleavage was approximately 
decreased around 30%. IETD is a substrate of caspase 8. However, in LPS-
induced mature DCs, all caspase activities were decreased by half fold (Figure 33). 
4.2.3 NOS is involved in the regulation of CD74 proteolytic degradation  
4.2.3.1 Proteolytic degradation of CD74 is inhibited in NOS2-deficient DCs 
In DCs, LPS induced NO production and NO acted as a caspase inhibitor 
in preventing CD74 degradation (Figure 33, 32A). Although NOS3 also  











Figure 32: NO inhibits CD74 protein degradation 
(A) (Left panel) Immature DCs derived from wild-type mice were either 
untreated (lane 1), or treated with L-NMMA (lane 2), LPS (lane 3), L-NMMA/LPS 
(lane 4), caspase inhibitor, CI (lane 5), or NONOate (lane 6). Protein extracts 
derived from various treatments were analysed by SDS-PAGE and Western blot. 
NOS2, CD74 and β-actin were detected by the corresponding antibodies (left 
panel). (Right panel) Macrophages were cultured in a medium alone (lane 7) or 
treated with either LPS (lane 8) or CI (lane 9). Cell extracts were separated by 
SDS-PAGE and analysed by Western blot. CD74 and β-actin were detected by the 
corresponding antibodies. (B) Total RNA was extracted from DCs treated as 
indicated in (A), and NOS2, CD74 and β-actin mRNA levels were determined by 
reverse transcription-PCR. (C) Immature DCs were treated with 1, 5, 10, 50 or 
100 1µM NONOate for 16 hours. Cell extracts were subjected to SDS-PAGE and 
a Western blot analysis. CD74 and β-actin were detected by the corresponding 
antibodies. The bars represent the density of CD74 bands, which are normalised to 
β-actin bands 






Figure 33: NO inhibits caspase activity 
(A) Cell extracts from immature DCs, induced with either LPS (grey bar) or 
NONOate (black bar) were incubated with different caspase substrates (as 
indicated), respectively, for four hours. The caspase activities were then measured. 
Data shown were the mean ± s.d. from three independent experiments. (p < 0.01)  
 
CHAPTER 4 NOS2 INTERACTS WITH CD74 
 127
contributed to NO synthesis to a lesser extent, the LPS-induced NO synthesis in 
DCs was mainly catalysed by NOS2 (Figure 28A). To verify whether it was 
indeed NOS2 taking part in the regulation of CD74, the NOS2 gene knockout DCs 
were used as a model. The wild-type and NOS2-/- mice were either untreated or 
treated with LPS and the cell lysate were subjected to a Western blot analysis. 
CD74 protein expression was then detected by the anti-CD74 antibody. As 
expected, in immature wild type and NOS2-/- DCs, the CD74 protein was 
undetectable (Figure 34 lane 1and 3). After induction with LPS, the CD74 
proteins in wild type DCs increased significantly (Figure 34, lanes 1 and 2). The 
expression of CD74 protein was also up-regulated in mature NOS2-/- DCs, but the 
up-regulation was obviously compromised compared with wild type DCs. This 
result indicated that NOS2 participate in the regulation of CD74, although there 
might also be other NOS genes, such as NOS3, that are involved in this regulation. 
4.2.3.2 NOS2 forms complexes with CD74 
Nitric oxide is a labile free radical gas that functions as a signalling and 
effector molecule in controlling a variety of cellular functions. Because of its 
potent reactivity and diffusibility, NO production by NOS2 is expected to be 
stringently controlled to ensure target specificity. One way to achieve target 
specificity is by forming stable NOS2-targeted protein complexes. NOS had 
previously been reported to form complexes with intracellular proteins (Bogdan, 
2001; Cao et al., 2001; Pritchard Jr et al., 2001). The interaction of NOS with 
specific heterologous proteins could be an effective mechanism to regulate the 
functions of these essential protein complexes. Based on our observations that 
CD74 was a substrate for caspases and NO could prevent the degradation of CD74 
presumably via its ability to inhibit caspase activities, it would therefore be  
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Figure 34: Proteolytic degradation of CD74 is enhanced in NOS2-deficient 
DCs 
Immature DCs derived from the wild type (grey bar) and NOS2-/- (black 
bar) mice were either untreated (control) or treated with 1 μg/mL LPS. Cell 
extracts were separated by SDS-PAGE and analysed by a Western blot. CD74 and 
β-actin were detected by the corresponding antibodies. The bars are representative 
of the density of CD74 bands, which are normalised to β-actin bands. 
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interesting to determine whether NOS2, the key enzyme that catalyses the 
production of NO in maturing DCs, could form complexes with CD74, thus 
regulating CD74 degradation. First, we examined whether CD74 co-localises with 
NOS2 in maturing DCs. LPS-induced DCs were double-labelled with CD74 and 
NOS2-specific antibodies and analysed by confocal microscopy. CD74 partially 
co-localised with NOS2 to the endosomal-like (Figure 35A) and endoplasmic 
reticulum (ER)-like (Figure 35A, B and C) structures in mature DCs. 
Next, we examined whether both NOS2 and CD74 could form a complex 
with each other. Co-immunoprecipitation studies using anti-NOS2 and anti-CD74 
antibodies showed that NOS2 indeed formed a complex with CD74 (Figure 35D), 
and this was consistent with the earlier co-localisation study (Figure 35A).  
4.2.4 Caspase 1 and caspase 11 are potentially involved in degradation of 
CD74 in DCs 
Because DCs treated with CI expressed higher level of CD74 protein, we 
next made attempts to identify the caspases that potentially utilise CD74 as a 
substrate. DCs were either untreated or treated with peptide-based caspase 
inhibitors: Z-VAD-FMK (for caspases 1, 3, 4 and 7), Z-WHED-FMK (for 
caspases 1, 4, 5 [11 in mouse] and 8), Z-YVAD-FMK (for caspases 1 and 4), or 
Ac-DEVD-CMK (for caspases 3, 6, 7, 8 and 10). All of the inhibitors except Ac-
DEVD-CMK elevated the CD74 protein level in DCs (Figure 36A). To determine 
the specificity of these inhibitors, DCs were incubated with various concentrations 
of either Z-WHED-FMK or Z-YVAD-FMK and then subjected to a Western blot 
analysis for the detection of CD74 protein expression. Although both inhibitors 
were able to inhibit CD74 degradation even at concentrations as low as 0.1 µM, 
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the inhibitory effect of Z-YVAD-FMK was relatively more specific than Z-
WHED-FMK, based on its ability to inhibit CD74 degradation in a dose-
dependent manner (Figure 36B). Due to the fact that Z-YVAD-FMK and Z-
WHED-FMK are strong inhibitors for both caspase 1 and caspase 11, it is highly 
possible that CD74 could be a substrate for either caspase 1 and/or caspase 11. 
Next, we investigated if both caspase 1 and 11 can form complexes with 
CD74. Co-immunoprecipitation studies using anti-NOS2 and anti-CD74 
antibodies showed that caspase 1 and 4 indeed formed complexes with CD74 
(Figure 36C). This further indicates that caspase 1 and/or 11 directly cleaves to 
CD74. 
4.2.5 N-terminus of CD74 contains a caspase cleavage site 
The screening of the amino acid sequence of the N-terminus of CD74 
revealed a putative caspase recognition/cleavage site “DQRD”. This cleavage site 
is conserved in various mammalian animals, including the rat, human, pig and 
cow (Figure 37A). 
Next, we investigated whether the DQRD motif was important for the 
intracellular localisation of CD74. Myc-CD74 (wild-type) and Myc-(D−A)CD74 
(D−A mutant) were expressed in DC2.4 cells and were detected using a specific 
antibody against c-Myc. Interestingly, a changing of the sequence “DQRD” motif 
to “DQRA” by point mutation did not cause a mis-localisation of CD74 in DCs 
(Figure 37B). 
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Figure 35: NOS2 forms complexes with CD74 
(A) Stereo 3D rendering images of NOS2 and CD74 subcellular localisation in 
DCs. Co-localisation of NOS2 (red) with CD74 (green) was viewed from two 
different angles. Z-scaling=0.49μm, Z-stack size=12.6μm, number of slices=26. 
(B−C) X-Z/Y-Z projection of collected confocal images showing co-localisation 
of NOS2 with CD74 from two different positions. Z-scaling=0.43μm, Z-stack 
size=14.18μm, number of slices=34. Stereo 3D rendering and X-Z/Y-Z projection 
were performed using the Volocity visualisation software from Improvision. (D) 
Protein extracts derived from LPS-treated DCs were immunoprecipitated with 
CD74 or NOS2 antibodies as indicated and sequentially probed with NOS2 and 
CD74 antibodies as indicated, by a Western blot (IP: immunoprecipitation; WB: 
Western blot analysis). 








Figure 36: Caspases are involved in the degradation of CD74 in DCs 
(A) Immature DCs were either untreated (control) or treated with several of 200 
mM caspase inhibitors): Z-VAD-FMK, Z-WHED-FMK, Z-YVAD-FMK and Z-
DEVD-CMK. Cell extracts were separated by SDS-PAGE and transferred onto 
nitrocellulose membrane. CD74 and β-actin were detected by the corresponding 
antibodies. (B) Immature DCs were either untreated (Ctrl) or treated for four 
hours with various concentrations (100, 10, 1, 0.1 μM) of Z-WHED-FMK or Z-
YVAD-FMK, and the cell lysates were subjected to a Western blot analysis for 
CD74 protein expression. CD74 and β-actin were detected with corresponding 
antibodies. Bars represent the densities of CD74 bands (normalised to β-actin 
bands). (C) Protein extracts derived from LPS-treated DCs were 
immunoprecipitated with caspase 1, 11, or NOS2 antibodies as indicated and 
sequentially probed with caspase antibodies, as indicated in the Western blot 
analysis. (RIgG: rabbit IgG isotype control, cell: input, Casp1: caspase 1 antibody, 
GIgG: goat IgG isotype control, Casp11: caspase 11 antibody; IP: 
immunoprecipitation; WB: Western blot analysis) 
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Figure 37: Caspase cleavage site on N-terminus of CD74 
(A) The amino acid sequences of the CD74 cytosolic domain from different 
animals were aligned. The red font indicates the conserved caspase cleavage site 
(upper panel). (B) DC2.4 expressing either Myc-CD74 (right panel) or Myc-(D−A) 
CD74 (left panel) were fixed and stained with antibodies against c-myc, followed 
by the FITC-conjugated anti-mouse IgG. Images were taken using the Olympus 
Fluoview 500 at 1000 × magnification. 
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4.2.6 “DQRD” motif is a caspase recognition and cleavage site 
To verify whether the “DQRD” motif was a caspase recognition and 
cleavage site, protein extracts derived from either untreated or CI-treated DCs 
[expressing either Myc-CD74 or Myc-(D−A)CD74,] were analysed by a Western 
blot analysis using antibodies against c-Myc and CD74. The degradation-
inhibitory effect of CI was more drastic on Myc-CD74 than on Myc-(D−A)CD74 
(Figure 38A, compare lane 3/4 and lane 5/6). In addition, we consistently 
observed that the quantity of total Myc-(D−A)CD74 proteins was significantly 
higher than the amount of Myc-CD74 proteins in the untreated DCs. This strongly 
suggested that the “DQRD” motif was indeed a caspase cleavage site and that 
D−A mutation significantly increased the stability of CD74 in DCs. As expected, 
CI-treatment increased the expression of endogenous CD74 as detected by IN−1 
monoclonal antibody (Figure 38A). To further confirm that CD74 was a substrate 
for caspases and that the “DQRD” motif on the N-terminus of CD74 was a 
caspase cleavage site, Myc-CD74 or Myc-(D−A)CD74 was expressed in DC2.4, 
immunoprecipitated using CD74-specific monoclonal antibody (IN−1) and 
digested with recombinant caspase 1 and caspase 4 in vitro prior to detection, 
using an anti-Myc polyclonal antibody. Immunoprecipitated Myc-CD74 but not 
Myc-(D−A) CD74 was preferentially cleaved by caspase 4 (Figure 38B, lane 3). 
On the other hand, Myc-CD74 was not cleaved by caspase 1 (Figure 38B, lane 2). 
However, it was worth noting that a small amount of Myc-(D−A)CD74 was 
cleaved by caspase 1 (Figure 38B, lane 2, lower panel). The reason for this was 
unclear, but there was a possibility that the D−A mutation on the “DQRD” motif 
might have created a site more receptive to caspase 1 activity. In addition, the 
“DQRD” motif was shown to be essential for the NOS2-CD74 interaction based 
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on the observation that wild-type Myc-CD74 but not the mutant Myc-(D−A)CD74 
interacted with NOS2 (Figure 38C). 
4.2.7 Over-expression of CD74 enhances MHC class II, CD80 and CD86 cell 
surface expression in immature DCs 
The importance of CD74 in MHC class II trafficking and antigen 
presentation has previously been reported (Matza et al., 2003). Based on the 
observations that NO treatment increased the expression of total CD74 protein and 
several essential endosomal protein molecules and at the same time up-regulated 
the cell surface expression of MHC class II, CD80 and CD86 in DCs, it was of 
great interest to determine whether an over-expression of CD74 alone could cause 
an increase in the cell surface expression of MHC class II and the two essential co-
stimulatory molecules CD80 and CD86 in immature DCs. Our results showed that 
an over-expression of either wild type (Myc-CD74) or D−A mutant CD74 (Myc-
(D−A)CD74) by mRNA electroporation enhanced the cell surface expression of 
MHC class II, CD80 and CD86 in immature DCs (Figure 39). Enhanced CD74 
expression alone could therefore result in an increase of MHC class II, CD80 and 
CD86 expression on the surface of immature DCs. 
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Figure 38: “DQRD” motif - a caspase recognition and cleavage site 
(A) DC2.4 cell extracts derived from either untreated or CI-treated DCs [expressing either Myc-CD74 or Myc-(D−A)CD74] were analysed by a 
Western blot, using antibodies against c-myc and CD74. Bars represent the density of myc bands normalised to β-actin bands. (B) Myc-CD74 
and Myc-(D-A)CD74 were expressed in DC2.4, immunoprecipitated using CD74-specific mAb (IN-1), and digested with recombinant caspase 1 
and caspase 4 in vitro prior to detection using anti-myc and anti-rabbit IgG polyclonal antibodies. (C) DC2.4 were transfected with Myc-CD74 
or Myc-(D−A)CD74 followed by induction with LPS. Cells were harvested, immunoprecipitated with anti-c-myc antibody, and probed with 
NOS2 and CD74 antibodies in a Western blot. The lysates were also precipitated with the corresponding isotype IgG.  




Figure 39: Over-expression of CD74 increases MHC class II cell surface expression 
(A-C) DCs were transfected (by electroporation) with luciferase (solid line), Myc-CD74 (purple line) or Myc-(D−A)CD74 (green line) mRNA. 
After a 24-hour incubation, cells were harvested and double-labelled with antibodies against CD80-FITC (A), CD86-FITC (B) or MHC class II-
FITC (C), followed by flow cytometric analysis. 
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4.3 Discussion  
4.3.1 NO partially promotes maturation of DCs 
Our studies in chapter 3 revealed that DC-CASPIC is one of the key 
molecules that regulate nitric oxide (NO) synthesis and thereby antigen 
presentation during maturation of DCs. In this chapter, I dissected the detailed 
mechanism of NOS/NO-enhanced antigen presentation during maturation of DCs. 
NO is a free-radical gas molecule that is implicated in a large number of 
fundamental cellular processes, such as vascular regulation, neurotransmission 
and immunity (Bogdan, 2001; Maniscalco et al., 2007). NO reacts in water with 
oxygen and its reactive intermediates yield (i) stable anions such as nitrite (NO2-) 
and nitrate (NO3-), (ii) unstable higher oxides such as nitrogen trioxide (N2O3), 
and (iii) unstable peroxides, peroxynitrite (ONOO-). In this study, our results show 
that NO can partially initiate maturation of DCs. Firstly, NO has the ability to 
induce the cell surface expression of MHC class II, CD80 and CD86 all of which 
are hallmarks of DCs going through maturation. In human monocytes, NO is 
reported to be involved in the acquisition of a more activated phenotype of DCs 
such as CD1a, CD80 and MHC class II (Fernandez-Ruiz et al., 2004). Moreover, 
the N-nitroarginine, an NO synthase inhibitor, produces a reversion of the 
phenotype of human mature DCs, induced by anion superoxide anion (Isenberg, 
2003). Secondly, similar to the effect of LPS (Wong et al., 2004; Santambrogio et 
al., 2005), No-donor NONOate treatment also causes an up-regulation of several 
essential molecules in the endosomal membrane trafficking pathways in DCs. 
Thirdly, NO-induced DCs acquire the capability to stimulate and enhance T cell 
proliferation in vitro. However, there are several reports showing that the NO/NO 
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donor, SNAP, or IFN-γ, inhibits alloantigenic T cell proliferation (Lu et al., 1996d; 
Katagiri et al., 2000). This inconsistency may be due to the different protocols 
used. In these studies, the NO donor was directly added into the DCs and T cell 
mixture, whereas in our study, the NO or NO donor was washed away before 
incubating with the T cells. Another reason may be that different types of the NO 
donor have been used, and thus different levels of NO may have been produced. A 
higher concentration of NO always accompanies cell apoptosis, whereas low 
concentrations of NO are able to selectively enhance the differentiation of helper 
T cells (Th1) (Niedbala et al., 2002).  
4.3.2 NOS2-CD74 partnership is essential to keep CD74 intact 
In LPS-induced DCs, the production and secretion of the endogenous NO 
correlates with NOS2 expression (Bonham et al., 1996). NO is a labile free radical 
molecule, which does not act through a receptor, but instead enters cells 
indiscriminately (Coleman, 2001). Therefore, the specificity of its action fully 
depends on its concentration and its proximity to target molecules. For NO to 
effectively exert its inhibitory actions on caspases via S-nitrosylation to protect 
proteins/complexes from proteolytic degradation, it is essential for it to be present 
in high, localised concentrations. Hence, it is critical for NOS to localise closely 
with proximity to target proteins/complexes. Interactions between NOS and 
several intracellular proteins have recently been reported by several laboratories 
(Cao and Eldred, 2001; Lo et al., 2001; Bogdan, 2001b). One of these reports has 
suggested that that interaction of NOS2 with the heat shock protein enhances the 
gp96-dependent production of NO in immature DCs (Panjwani et al., 2002). Our 
study shows that NOS2 partially co-localises, and more interestingly, interacts 
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with CD74 in DCs. Thus, NOS2, which is in proximity to CD74, could catalyse 
the production of sufficiently high, localised concentrations of NO to protect 
CD74, as well as other endosomal membrane trafficking related proteins, from 
caspase-dependent degradation.  
Furthermore, point mutation and co-immunoprecipitation studies revealed 
that the association of NOS2 and CD74 is dependent on the “DQRD” motif on the 
cytosolic domain of CD74. However, LPS-induced NOS2 without NO synthesis 
(in the presence of L-NMMA that inhibits the activity of all three forms of NOS) 
did not reduce CD74 degradation. Thus, the possibility that NOS2 binding to 
CD74 might have prevented caspases from accessing the recognition/cleavage site 
(“DQRD”) on the N-terminus of CD74, by inducing either steric hindrance or 
conformational change, is excluded. 
Although the “DQRD” motif is essential for both recognition/cleavage by 
caspases and for the interaction between of NOS2 and CD74, there is a possibility 
that the binding of caspases to the N-terminus of CD74 is independent of NOS2 
binding. In immature DCs where the expression of NOS2 is low, caspase binds to 
the “DQRD” motif and cleaves CD74 efficiently. However, upon induction by 
LPS that initiates maturation of DCs, the expression of NOS2 increases. NOS2 
then binds to the N-terminus of CD74 in proximity to the “DQRD” motif. 
Although this binding of NOS2 does not interfere with the binding of caspases to 
the “DQRD” motif, it can catalyse the production of NO, which inhibits caspases 
and prevents CD74 degradation. Thus, the NOS2-CD74 partnership is essential to 
keep CD74 or its complexes intact. In fact, it is of great importance for CD74 to 
bind to NOS2 immediately after synthesis and to be inserted into the ER 
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membrane. This is consistent with our observation that NOS2 co-localises with 
CD74 on the ER-like membrane structures in maturing DCs. Although NOS2 is a 
cytosolic protein, it has been reported that NOS2 trafficks with vesiculotubular 
structures to dendritic clusters in hippocampal neurons (Wu et al., 2000). 
Moreover, NOS2 is also able to bind to several membrane proteins, such as NAP-
110 and kalirin in which the functional significance of these interactions has not 
yet been established (Navarro-Lerida et al., 2006).  
4.3.3 Both NOS2 and NOS3 are involved in the regulation of CD74 
The protein expression level of CD74 was low in both the wild type 
(NOS2+/+) and NOS2-/- immature DCs. As expected, after treatment with LPS, the 
expression of CD74 in wild type DCs increased dramatically. Interestingly, we 
also observed an increase of CD74 expression in NOS2-/- DCs after LPS induction, 
suggesting that other LPS-inducible forms of NOS might also be involved in 
protecting CD74 from degradation during maturation of DCs. In this case, NOS3 
could be the likely candidate based on the following reasons: (i) Currently, there 
are three known forms of NOS (NOS1, NOS2 and NOS3) of which only NOS2 
and NOS3 have been shown to be expressed in non-neuronal cells (Hickey et al., 
1997); the results show that DCs expressed NOS3 and the expression of NOS3 
was inducible by LPS; (ii) The activity of NOS2 is partially dependent on the 
expression of NOS3 (Vo et al., 2005; Connelly et al., 2005).  
4.3.4 CD74 is one of the substrates of caspases 
The MHC class II-associated invariant chain, CD74, was one of the 
molecules up-regulated in DCs after treatment with either LPS or NONOate. 
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CD74 is essential for proper MHC class II folding in the ER, and for targeting 
MHC class II-CD74 complex to the endosomes (Becker-Herman et al., 2005; 
Busch et al., 2005). In the endosomes, CD74 protein undergoes degradation via 
several stepwise proteolytic processes (executed by various specific proteases), 
forming cleavage products, p31, p22 and p10. The final protease cleavage product, 
CLIP (a product derived from the cleavage of p10), a short peptide of 23 amino 
acids, remains bound to the peptide-binding groove of the MHC class II-αβ 
complex. Every proteolytic step is executed by specific proteases and the cleavage 
of proteins could be one of the mechanisms employed by cells to regulate protein 
expression levels at various stages of cell development. During maturation of DCs, 
the activities of proteases such as caspases are repressed, resulting in the 
accumulation of a number of endosomal proteins (Wong et al., 2004). In 
conjunction with this, the full-length CD74 protein (p31) is also up-regulated upon 
DC maturation (Engering et al., 1998; Gomez et al., 2004 and this study). An 
unaltered CD74 mRNA level in DCs after treatment with LPS excludes the 
possibility of up-regulation at the transcriptional level. Although several major 
proteases involved in the terminal stages of CD74 processing have been identified, 
very little is known about how the proteolytic degradation of CD74 was regulated 
in maturing DCs. A previous report has suggested that asparagine endopeptidase 
(AEP) was involved in the degradation of CD74 protein in B cells (Manoury et al., 
2003). However, no difference in the processing of the CD74 has been observed 
between AEP-deficient and wild type mice (Maehr et al., 2005). Our results 
strongly suggest that caspase could be one of the major proteases that 
cleaves/degrades CD74 based on the observations that (i) the inhibition of 
caspases activity by the caspase inhibitor (CI) results in the accumulation of CD74 
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proteins; (ii) CD74 coimmunoprecipitates with caspase 1 and caspase 4; and (iii) 
the immunoprecipitated Myc-CD74 protein is a cleavage substrate for caspases in 
vitro. A screening of the N-terminal cytoplasmic domain of CD74 identified one 
potential caspase recognition/cleavage site, “DQRD”, which is conserved in 
humans, mice and rats. In addition, the motif “DQRD” has been shown to be a 
specific cleavage site for caspase 3 (Houde et al., 2003). In this study, however, a 
caspase 3-specific inhibitor was not able to inhibit the degradation of CD74 in 
DCs. Further experiments using recombinant caspase 1 and caspase 4 have shown 
that myc-CD74, but not myc-(D−A)CD74 is preferentially cleaved by 
recombinant caspase 4. Furthermore, the disruption of the “DQRD” motif by point 
mutation [myc-(D−A)CD74] significantly increases the half life of CD74, further 
supporting the hypothesis that the “DQRD” motif is a caspase 
recognition/cleavage site.  
Previous studies have suggested that caspase activity in immature DCs is 
relatively high and that activity is significantly inhibited in mature DCs by a 
mechanism closely linked to the activity of NOS2. NOS2 catalyses the synthesis 
of NO, which may in turn S-nitrosylate the catalytic domain of active caspases 
(Rossig et al., 1999; Tannenbaum and White, 2006). This is consistent with our 
observation that CD74 degradation is repressed by treating immature DCs with 
the NO donor (NONOate).  
Our results show that CD74 is a substrate for caspases and that the N-
terminus of CD74 contains a single caspase cleavage site. Cleavage at the N-
terminus of CD74 by proteases is plausible based on the fact that it is the only part 
of the CD74 molecule that is exposed to the cytoplasm. Since CD74 degradation 
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is inhibited in the presence of caspase inhibitors, it is likely that cleavage at the N-
terminus by caspases alone could initiate the degradation of CD74. In addition, 
based on the localisation of CD74 on the ER-like compartment in maturing DCs, 
there is a possibility that the degradation of CD74 could be initiated by caspase 4 
on the cytoplasmic surface of the ER membrane in DCs. This is supported by 
previous reports that caspase 4 is one of the caspases inhibited during DC 
maturation and caspase 4 is localised to the ER membrane (Nakagawa et al., 2000; 
Wong et al., 2004; Hitomi et al., 2004; Kim et al., 2006). Caspase 4 has been 
shown previously to be essential for cytokine maturation and inflammation, and it 
has been reported to play key roles in ER stress- and amyloid-β-induced cell death 
(Kamada et al., 1997; Hitomi et al., 2004). Although caspase 4 is shown here to 
cleave and presumably to initiate CD74 degradation in DCs, the mechanism that 
regulates such an event is still unclear. While our results indicate that the 
degradation of CD74 could be initiated on the ER membrane, based on the ER-
localisation of caspase 4, we could not exclude the possibility that CD74 is 
degraded after being targeted to the endosomes. This is supported by the fact that 
an N-terminus deleted CD74 construct, which has the endosomal targeting 
dileucine motif restrained, is still able to target to the endosomes (data not shown). 
Further experiments along this line will shed more light on this issue. 
4.3.5 Increased CD74 enhances the function of DCs 
The protection of CD74 from degradation could be one of the mechanisms 
that contribute to the increase in antigen presentation efficiency in maturing DCs. 
Previous studies showed that both p31 and p41 forms of CD74 promote MHC 
class II antigen presentation in mouse fibroblast cells (Serwe et al., 1997). This is 
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consistent with our observation that the inhibition of CD74 degradation by either 
the exogenous NO or the over-expression of NOS2 accompanies an increase in 
MHC class II cell surface expression in DCs. In addition, the over-expression of 
CD74 by mRNA electroporation in DCs increases the cell surface expression of 
CD80/CD86 and MHC class II. 
This further supports our model that NO is the key molecule that inhibits 
the caspase-dependent degradation of CD74 and other endosomal proteins during 
LPS-induced DC maturation. Controlling the half life of these proteins is thus 
vital in regulating the trafficking of the MHC class II complex and antigen 
presentation during DC maturation. It has been recently shown that proteolytic 
peptides derived from CD74 are able to modulate cell proliferation and survival 
(Starlets et al., 2006). Thus, the regulation of the CD74 half life by caspases could 
have contributed significantly to the signalling cascades that control cell 
proliferation and survival. 
4.3.6 Conclusion 
The post-translational regulation of CD74 plays an important role in MHC 
class II trafficking and antigen presentation in DCs. Nevertheless, the post-
translational regulation of CD74 is rather complicated and has not yet been fully 
elucidated. Hence, the primary objective of this study is to investigate a new 
pathway of CD74 post-translational regulation. A novel CD74 regulatory pathway 
involving caspases and NO has been identified. 
To determine whether caspases are involved in the post-translational 
regulation CD74, DCs were treated with various types of caspase inhibitors and 
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their effects on the expression of CD74 were examined. All of caspase inhibitors 
except the caspase 3 inhibitor up-regulated the CD74 protein. In addition, the co-
immunoprecipitation of caspases 1 and 4 with CD74 indicates the interaction of 
CD74 with these caspases. The mutations of the caspase cleavage site from 
DQRD to DQRA, which lies on the N-terminus of CD74, diminished the 
accumulation of CD74. Consistent with our results, it was also found that the 
caspase activity decreased during the maturation of DCs. From these observations, 
a new pathway can be illustrated. During the maturation of DCs, the caspase 
activity decreases and results in the accumulation of its substrate CD74. The up-
regulation of CD74 provides DCs with the antigen-presenting capability. In this 
study, although different types of caspase inhibitors have been employed, the 
results presumably exclude solely the possibility of caspase 3, because it would be 
rather difficult to monitor the inhibitors’ specificity under the physiological 
conditions. Nevertheless, the involvement of caspases in CD74 post-translational 
regulation as reported in this study has undoubtedly opened a new area in 
immunoregulation, because caspases have long been thought to act primarily as 
inducers of apoptosis. On the other hand, there are also other CD74 regulation 
pathways in DCs, such as the cathepsin-mediated pathway. It would therefore be 
interesting to investigate the relationship between the caspase-mediated pathway 
and the other regulatory pathways in CD74 regulation. DCs from caspase 
knockout mice would undoubtedly provide useful information. The knockout 
studies would also help to identify the specific caspases involved in the pathway. 
In this study, factors at the upstream of caspase-mediated CD74 regulation 
pathway have also been investigated. The exogenous NO donor, NONOate, has a 
similar effect on on the accumulation of CD74 as caspases in DCs. This may be 
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due to the S-nitrosylation of caspases by NO [Rossig L, 1999]. In DCs, the 
production and secretion of endogenous NO are induced by LPS and are mainly 
correlated with NOS2 expression. However, too much NO is undesirable because 
NO is a labile free-radical molecule, which may cause damage to the cells, and at 
the same time, it is an effector molecule controlling a great variety of 
physiological functions in DCs such as cell migration, cytokine production as well 
as apoptosis [Giordano D,2006, Lu L, Bonham, 1996]. Therefore, NO level and 
thus the activity of NOS2 must be tightly regulated in DCs. Our data show that in 
DCs, NOS2 is present in the same intracellular compartment as CD74, such that 
NO will be produced adjacent to CD74 molecules. Therefore, NO could attain a 
gradient concentration sufficient to protect CD74 from caspase cleavage, but with 
limited undesirable effects. Furthermore, our mutagenesis and 
immunoprecipitation experiments have revealed that the association of NOS2 and 
CD74 is dependent on the caspase cleavage site, which lies in the cytosolic 
domain of CD74. In addition, the induction of NOS2 without NO production 
exerts no effect on the accumulation of CD74. This has excluded the possibility 
that the NOS2 protein itself prevents caspases from accessing to the cleavage site 
on the CD74 through steric hindrance or through inducing conformational changes 
in CD74. In future work, in vitro protein-protein interaction experiments using 
purified bacteria-produced fusion proteins of both NOS2 and CD74 would be 
useful to study whether or not CD74 interacts with NOS2.  
Although the loss of NOS2 increases the cleavage of CD74 and that 
exogenous NO antagonises this effect in DCs, the accumulation of CD74 in LPS-
induced NOS2-knockout DCs suggests that other isoforms of NOS might also be 
involved in the regulation of CD74 in DCs. We thus propose that NOS3 could be 
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such a candidate: firstly, there are only three isoforms of NO synthase, namely 
NOS1, NOS2 and NOS3, of which NOS1 is not expressed in DCs; secondly, the 
activity of NOS2 at least partially depends on NOS3; thirdly, NOS3 also binds 
directly to one of the antigen-presenting-related proteins, dynamin, which is 
subjected to cleavage by caspases (Connelly L, 2005, Vo PA 2005).  
Due to the limitation of the low specificity of the NOS3 antibody and the 
low level of endogenous NOS3 expressed in DCs, the experiment of the co-
immunoprecipitation of NOS3 with CD74 was not been carried out. Thus, the 
question of whether NOS3 forms a complex with CD74, as NOS2 does, has yet to 
be answered. Although it would be rather difficult to verify the direct interaction 
between NOS3 and CD74, gain-of-function and lost-of-function studies using 
electroploration and gene knockout have revealed that NOS3 has a similar effect 
on the distribution of MHC class II and on the stimulation of T cells in DCs. 
These results suggest that the trafficking of MHC class II to the cell surface and 
the stimulation of T cells in DCs are dependent on the NOS3 protein. Further 
studies are needed to switch from an in vitro study to an in vivo study for the 
identification of the potential pre-clinical significance of this caspase-NOS 
mediated CD74 regulation pathway. As a first step, the NOS2/NOS3 gene-
modified DCs may be re-injected into the mice, together with suitable antigenic 
peptides followed by a monitoring of the effects on the immunoresponse of the 
mice, such as cytokine secretions or T cell proliferations. 
In summary, in this study, we have found that CD74 is cleaved by 
caspases in DCs. During the maturation of DCs, the decrease of caspase activities 
owing to the S-nitrosylation by NO causes an accumulation of CD74. CD74 in 
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turn increases the cell surface expression of MHC class II and thus the antigen 
presentation ability of DCs. On the other hand, NO is mainly generated from 
NOS2 which is found to have a direct interaction with CD74. This direct binding 
protects the caspase cutting site “DQRD” in the CD74 N-terminus from caspase 
cleavage (Figure 40). In addition, NOS3 may also play a role in the protection of 
CD74. Taken together, these findings have shed new light on the post-
translational regulation of CD74. Together with the current knowledge on the 
transcriptional and translational regulation pathway of NOS3 and NOS2, these 
findings may provide a convenient platform to engineer the functions of DCs and 
to develop or design potent vaccines against infectious diseases and cancers. 
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Figure 40: Model shown that NOS2 activity is essential in preventing CD74 proteolytic degradation in maturing DCs 
In immature DCs, the cytoplasmic domain of CD74 is exposed to the proteolytic activity of caspases. During DC maturation, NOS2 binds to the 
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